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 Streptococcus pneumoniae is a major pathogen that causes Otitis Media infections and 
bacterial meningitis in children as well as community acquired pneumonia in adults. Clinical 
isolates of S. pneumoniae exhibiting resistance to β-lactam antibiotics are being isolated with 
increased frequency in many countries. Altered penicillin-binding proteins is the main 
mechanism of resistance that S. pneumoniae has acquired. The acquisition of this resistance 
mechanism has been attributed to horizontal gene transfer mediated especially by the natural 
transformability of S. pneumoniae. Other mechanisms of resistance to β-lactam antibiotics in S. 
pneumoniae are less known.  
 This study was focused on S. pneumoniae and its increased level of resistance to β-lactam 
antibiotics. Eleven clinical isolates from Duke University in Durham NC, Grady hospital in 
Atlanta, GA and one from Boston, MA Hospital were used in the first phase of my research. In 
addition, this study included six strains obtained from the Centers for Disease Control and 
Prevention (CDC), Atlanta, GA., which were used in the formulation of one widely used 
pneumococcal polysaccharide vaccine. All strains were tested for suseptibility to amoxicillin, 
ampicillin, ceftazidime and vancomycin. Representative strains were also tested for susceptibility 
to penicillin G. All of the clinical isolates exhibited high levels of resistance to at least one 
antibiotic. One strain in particular, Sp D2 was resistant to all of the β-lactams tested, but was 
susceptible to vancomycin, the only non-β-lactam used in the first phase. These strains were also 
characterized by SDS-PAGE to compare their whole-cell protein profiles.  The proteins in the 
highly resistant strain (Sp D2) exhibited a unique SDS-PAGE profile with one especially highly-
resolved band with a molecular weight of approximately 50 kDa that was not present in any 
 xi
other strain. Additional SDS-PAGE analysis also revealed that the Sp D2 protein band of interest 
may represent two proteins. 
 The unique band exhibited by Sp D2 was further characterized by membrane protein 
extraction, followed by In-Gel Trypsin digests. The resulting peptide digests were analyzed 
further using MALDI-MS (matrix assisted laser desorption and ionization mass spectrometry). 
Spectra obtained from the tandem mass spectrometry analysis were used to search databases for 
peptide sequence homologies. The resulting MALDI-MS data did not produce any significant 
matches with proteins in any of S. pneumoniae published genome databases.   In addition, N-
terminal and Internal sequencing performed at Emory’s Microchemical Facility did not result in 
any significant matches; thus, indicating the possibility of a new protein. 
 We consultation with Dr. Keith Klugman a Professor in the Infectious Diseases/ 
International Health Department at the Emory School of Public health and Dr. Richard Facklam 
of the Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, 
CDC, about my initial thesis results. Both individuals are members of the worldwide Active 
Bacterial Core Surveillance/Emerging Infections Program Network. They expressed immediate 
interest in the results I had obtained and stressed that the unique characteristics exhibited by Sp 
D2 could be of great importance and of international significance. They informed us that Sp D2 
exhibited levels of resistance to β-lactam antibiotics rarely documented. The constant monitoring 
of drug resistant strains are essential in planning for effective treatment and/or vaccine 
development.  
We therefore initiated collaboration with Dr. Facklam and the Active Bacterial 
Core Surveillance/Emerging Infections Program Network at CDC to further study Sp D2 
and expanded my research to include the other clinical isolates presented in my thesis. 
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Phenotypic characterization of strains is not always reliable since they are influenced by 
environmental changes such as pH, temp etc. It was therefore necessary to confirm that 
Sp D2 was in fact a Streptococcus pneumoniae. This was especially important since the 
protein study results did not receive a match with the three sequenced S. pneumoniae 
genomes. This second phase of my research included serotyping (capsule based), 
extensive susceptibility testing as well as PCR studies targeting genes that conclusively 
identify S. pneumoniae and that encode proteins being considered as candidates for new 
vaccine development. 
Sp D2 was found to be non-typeable and therefore could not be assigned a capsule 
type. This is unusual since 99% of S. pneumoniae strains are typeable. Which means that 
the current capsular polysaccharide vaccine would not be active against an Sp D2 
infection. Additional biochemical tests by bile solubility and optochin tests showed Sp 
D2 to be positive for both tests, a characteristic of most S. pneumoniae strains. PCR of 
the pneumococcal surface protein gene (psaA), Autolysin gene (lytA) and pneumolysin 
gene (ply) showed that Sp D2 contained all three genes. Sp D2 was therefore positively 
identified as a S. pneumoniae strain, though non-typeable. Two other clinical isolates Sp 
G-5481 and Sp Original were also non-typeable. All the other clinical isolates were 
positive for psA and lytA by PCR. Two strains, Sp G-31159 and Sp G-5481 were negative 
for the presence of ply. Both strains still identified as fitting the profile of S. pneumoniae.  
Additional antibiotic resistant tests on Sp D2 revealed resistance all β-lactams 
tested, including cephalosporins. This means that Sp D2 infections could be treated with 
any β-lactam antibiotic. It is also resistance to erythromycin which is a macrolide. Sp D2 
was found to be susceptible to four antibiotics, chloramphenical, tetracycline, 
 xiii
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clindamycin (a macrolide), levofloxacin and vancomycin. However, tetracycline, 
clindamycin and levofloxacin are not suitable for treatment of meningitis. This leaves 
only chloramphenical and vancomycin. Unfortunately, vancomycin must be administered 
intravenously to treat pneumococcal infections and its use tends to select for vancomycin-
resistant Enterococci. The fluoroquinolones have the drawbacks of being quite broad in 
spectrum and relatively expensive. Thus an infection or outbreak caused by Sp D2 would 











INTRODUCTION AND BACKGROUND 
 
Taxonomy of S. pneumoniae 
Streptococcus pneumoniae is an important bacterial pathogen worldwide. This 
organism is a member of the normal microflora of healthy children and adults, but can 
sometimes cause infections. S. pneumoniae can cause invasive infections such as 
pneumonia, meningitis, and septicemia, as well as localized infection in children known 
as Otitis Media (2, 36, 56, 77). Acute Otitis Media is one of the major causes of 
morbidity in children (30). The most severe forms of Otitis Media is caused by three 
pathogens, S. pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. The 
focus of my research is only on S. pneumoniae. 
 Otitis media is an infection of the middle ear that occurs when the Eustachian tube 
fails to properly drain fluid (30). The Eustachian tube in infants is shorter, wider and 
more horizontal than in older children and adults. Also, the cartilage supporting the 
Eustachian tube in infants is floppy, and cannot properly drain the middle ear fluid. 
Consequently, infection occurs when bacteria migrate from the nasopharynx into the 
Eustachian tube and proliferate, therefore activating the inflammatory response resulting 
in tissue damage and Otitis Media. 
 Treatment and management of Otitis Media infections caused by S. pneumoniae 
currently involve chemotherapy with antimicrobial agents, and/or immunizations with the 
pneumococcal polysaccharide vaccines. Several different groups of antimicrobial agents 
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are used by physicians to treat patients. Knowledge of the causative agents, and their 
antimicrobial susceptibility patterns are essential to guide the appropriate selection of 
antimicrobial agents to use in chemotherapy.  
 When evaluating taxonomic information on clinical isolates, scientists and 
physicians must consider three broad categories of fundamental biological information 
that pertain to bacterial pathogens: (i) criteria used to definitively classify a clinical 
isolate into a Genus and species, (ii) intra-species differentiation such as serotypes, 
resulting from strain-to-strain variation, and (iii) variation in expression and regulation of 
genes that encode virulence factors. 
 
Phenotypic Characteristics of S. pneumoniae 
 Since S. pneumoniae is an important pathogen, correct identification and 
characterization is critical. For routine clinical laboratories, identification of pneumococci 
has been determined on the basis of several phenotypic characterization methods (2, 36, 
62).  
S. pneumoniae is a gram positive organism that is identified by using several 
phenotypic tests including selective and differential growth media. When cultivated on 
blood agar plates, this organism exhibits a characteristic greenish halo around colonies. 
This is alpha hemolysis resulting from partial lysis of red blood cells. Other Streptococci 
such as S. pyogenes exhibit beta hemolysis which is total red blood cell lysis. The bile 
solubility test is yet another method used to identify S. pneumoniae. The organism 
produces an enzyme called amidase that cleaves specific covalent bonds in the 
peptidoglycan layer. This enzyme is activated by bile or bile salts such as sodium 
 2
deoxycholate. Another test is the Optochin test which is a presumptive test that is used to 
identify strains of S. pneumoniae. Optochin is a surface-active agent that specifically 
interacts with the cell membrane to produce cell lysis (2). Three phenotypic tests 
(optochin susceptibility, bile solubility, and agglutination with the antipneumococcal 
polysaccharide capsule antibodies) were previously used to differentiate classical S. 
pneumoniae from other alpha hemolysis Streptococci (90).   
 
Antimicrobial Susceptibility Testing 
Following presumptive identification, it is necessary to inform physicians of 
susceptibility patterns of the organisms. In a clinical setting, S. pneumoniae susceptibility 
patterns are routinely obtained. This is especially important in that it helps in selection of 
antibiotics to use for treatment. The agents routinely used to treat S. pneumoniae 
infections are discussed in more detail below (page 12). 
 
Other Specialized Tests for Characterization of S. pneumoniae 
 While phenotypic characterization is useful for convenience, they are however not 
always reliable. This is because phenotypic properties are influenced by many 
environmental factors such as pH, temperature, age of culture etc. To provide more 
definitive information for proper identification of organisms, molecular techniques are 
being used especially in epidemiological studies of outbreaks. Several categories of 
molecular biological assays are used. 
Some immunological based tests include antibody assays to detect specific 
pathogens. This can also be used to differentiate between strains of the same species. 
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ELISA (Enzyme-linked immunosorbent assay) measures antibodies to whole cells and/or 
cellular components. Western blot analysis allows one to visualize antibodies directed 
against a specific protein usually on an SDS-PAGE gel. The immunological based tests 
are highly accurate however their main disadvantages include expense and time involved 
in raising antibodies. They also require reagents in which all serotypes are represented 
(61). 
SDS-PAGE analysis can be used to for whole cells protein analysis or analysis of 
specific fractions such as cytoplasmic membranes and outer membranes of gram-negative 
bacteria. This is an important molecular epidemiological tool because it generates a 
profile that can distinguish between strains that otherwise may have very similar 
characteristics based on phenotypic and biochemical tests (76). This is especially 
important in identification of atypical strains. 
Some other molecular based tests that can be used to identify S. pneumoniae 
include nucleic acid hybridization and PCR to detect specific characteristic genes. The 
current PCR techniques are especially useful due to the accuracy and speed involved in 
obtaining results.  
 
Virulence Factors of S. pneumoniae 
Capsule 
S. pneumoniae encapsulated strains have been shown to be more virulent than 
those without a capsule. The study of pneumococcal capsule was the object of many 
investigations that led to important scientific discoveries. In 1928, Griffith showed that 
when heat-killed encapsulated pneumococci and live strains lacking a capsule were 
 4
together injected into mice, the none capsulated strain could be converted into 
encapsulated pneumococci and kill the mice. Years later, the carrier of this genetic 
information was shown to be DNA (2). 
Serotyping of S. pneumoniae is important because there have been changes in the 
distribution of  types isolated from invasive diseases over a period of time in a single 
locality. This is important with reference to vaccine formulations. Differences in the 
capsular types that are isolated from different age groups and regional differences in 
distribution of types have also been reported (44). 
 The capsule has long been recognized as the major virulence factor of S. 
pneumoniae. The chemical structure of the capsular polysaccharide and, to a lesser 
extent, the thickness of the capsule determine the differential ability of the strains to 
survive in the bloodstream and possibly cause invasive disease (2). The capsule prevents 
binding of antibodies to the cell wall of pneumococci and thus inhibits phagocytosis. 
 Pneumococci can be divided into 90 serotypes on the basis of difference in 
capsular polysaccharide structure but most cases of invasive infections appear to be 
caused by twenty three serotypes (2, 35). The currently licensed 23-valent polysaccharide 
pnemococcal vaccine which is only moderately effective contains twenty three purified 
capsular polysaccharide antigens; serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F (36). The serotypes 6B, 9V, 14, 
19A, 19F, and 23F cause most drug-resistant infections in the United States (36).  
The distribution of types isolated from adults differs substantially from that of 
types isolated from children. Some studies have shown that the most important pediatric 
serotypes, 6A, 14, 19F and 23F were responsible for almost 60% of all infections. In 
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adults however, serotypes 3, 19F and 6A accounted for only 31% of the isolates (2). The 
geographical distribution and prevalence of serotypes differ worldwide. Twenty serotypes 
are responsible for ~ 90% of all reported infections in the United Sates and Europe, 
whereas, for instance, the 23-valent vaccine, which contains these serotypes is effective 
against <70% of pneumococcal infections in Asia (2). In 2000, a 7-valent protein-
polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed 
in the Unites States for use in young children (92). 
 
Pneumococcal Surface Antigen  
 PsaA gene in S. pneumoniae encodes a protein which functions to transport Mn2+ 
and Zn2+ into the cytoplasm (36, 51). Pneumococcal surface antigen A (PsaA) is a 
virulence factor of pneumococci and has a molecular weight of approximately 37 kDa 
(37, 61). The absolute determination of PsaA specificity for Mn2+ and/or Zn2+ still 
remains to be answered. However, growth requirements of PsaA- mutants suggest that 
PsaA plays an essential role in the transport of Mn2+ into the cytoplasm of pneumococci 
(36). Mutations in psaA result in growth limitation in low manganese(51). PsaA elicits 
protective properties in mice against S. pneumoniae and the PsaA- mutants of 
pneumococci were also avirulent in a mouse model (36). Marra et al examined the 
expression of psa operon in vivo and the virulence of deletion mutants were assessed in 
different animal models of infection. The results demonstrated that psaA mutants were 
completely attenuated in systemic, respiratory tract and Otitis media infections. In 
addition, the mutants were unable to grow in an implanted peritoneal chamber, but 
growth was restored by the addition of manganese to the chambers (51)   
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 There is still a debate on whether PsaA protein plays a role in pneumococcal 
adhesion. Some investigations of PsaA have suggested that this molecule is not an 
adhesin, as initially thought. The lipid-linked PsaA protein, with dimensions of 40 by 40 
by 70 Å, is probably present beneath the peptidoglycan and capsule structures of 
pneumococci (36). The total thickness of the pneumococcal cell wall is approximately 
~0.36 µm, therefore PsA has no possibility of protruding outside the cell wall (36). Other 
studies involving mutation analysis demonstrated that changes in PsaA protein affect the 
binding of S. pneumoniae, indicating that PsaA plays a critical role in bacterial adherence 
and virulence (37).   
 Morrison et al demonstrated the presence of psaA in all 90 serotypes that were 
tested, and that there was lack of amplification of heterologous organisms. This suggested 
that PCR amplification of psaA could be a very useful tool for detection of pneumococci 
and diagnosis of disease. This study showed that a protein common to all serotypes with 
genetic and immunologic similarity has implications for both vaccine studies and 
diagnostics development. It meant that the use of an immunogenic common protein as a 
vaccine could eliminate the need for multiple capsular types in a pneumococcal vaccine 
and additionally elicit a memory response, which occurs only with protein-based vaccines 
(61).  
 Genomic sequence analysis shows that PsaA belongs to an ATP binding cassette 
(ABC)-type transport system and constitutes the extracellular component responsible for 
solute (metal) binding (36).  The ABC-type transport system is characteristic of 
prokaryotic and eukaryotic cell and has several domains. The individual domains can be 
expressed as separate proteins or may be fused into multidomain polypeptides in variety 
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of ways (68). It has an extra-cytoplasmic protein responsible for solute binding (such as 
PsaA), an integral membrane part responsible for transport of the solute through the cell 
membrane, and a cytoplasmic protein binding ATP. ATP binding cassette (ABC)-type 
multidrug transporters use the free energy of ATP hydrolysis to pump drugs out of the 
cell, the so called efflux pumps (68). This has been demonstrated in several bacteria. 




 Pneumolysin (Ply) is a virulence factor of pneumococci that penetrates the 
physical defenses of the host. It is a 53-kDa protein produced by most clinical isolates of 
the pathogen (36). Unlike other pneumococcal antigens, this molecule is not surface 
exposed. It is a cytoplasmic enzyme that is released due to the action of the surface 
pneumococcal autolysin (2, 36). The enzyme is cytotoxic to ciliated bronchial epithelial 
cells and slows beating in organ culture (2).  
 Pneumolysin is part of a larger group of proteins of pathogenic gram-positive 
bacteria known as cholesterol-dependent cytolysins. All of them are virulence factors for 
their organisms (36). Their mode of action is based on binding to the host cytoplasmic 
membrane cholesterol, a process that is followed by insertion into the targeted 
membranes and formation of relatively large pores. Once the pores are formed, the 





 Autolysins are members of a widely distributed group of enzymes that degrade 
the peptidoglycan backbone of bacteria (36). The action of these cell wall degrading 
enzymes ultimately lead to cell lysis. An example of one such enzyme is the S. 
pneumoniae N-acetylmuramoyl-L-alanine amidase, also known as LytA amidase. LytA 
has a molecular mass of ~ 36 kDa and has been implicated in the pathogenesis of 
pneumococci. One of the direct implications is the release of the components of cell wall 
shown to be highly inflammatory in animals (36). The indirect implication involves the 
release of cytoplasmic bacterial proteins including pneumolysin discussed above.  
 The precise role of LytA in virulence is still however under debate. Berry et al, 
demonstrated that mutations of LytA gene in the S. pneumoniae chromosomes leads to 
significantly decreased virulence of this organism compared to wild-type strain in mouse 
intraperitoneal challenge (6). Other studies of LytA also have shown that this amidase 
induces a protective response in mice to streptococci when inoculated in the lungs (11). 
This protective property of LytA that contributed to a significantly longer survival for 
mice challenged intranasally with autolysin makes it a potential component of novel anti-
pneumococcal vaccines (36). 
 
Alternative Approaches to Vaccine Development and Diagnosis of S. pneumoniae 
(Importance of  PsaA, Ply and LytA study) 
As discussed earlier, pneumococci can be divided into ~90 serotypes on the basis 
of difference in capsular polysaccharide structure but most cases of invasive infections 
appear to be caused by twenty three serotypes (2, 35). The distribution of types isolated 
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from adults differs substantially from that of types isolated from children. The 
geographical distribution and prevalence of serotypes differ worldwide. Twenty serotypes 
are responsible for ~ 90% of all reported infections in the United Sates and Europe, 
whereas, for instance, the 23-valent vaccine, which contains these serotypes is effective 
against <70% of pneumococcal infections in Asia (2). 
The existence of many pneumococcal serotypes has complicated further 
development of the current capsular polysaccharide classes of vaccines. Although these 
vaccines cover the most prevalent serotypes found in the population at risk, they protect 
mainly against illness caused by those serotypes included in the vaccine. Further more, 
the current 23-valent polysaccharide vaccine poorly induces antibody responses in young 
children under the age of two years old and thus does not effectively protect against 
either invasive or local pneumococcal infections (77). The problems with the current 
vaccine has stimulated an interest in the need for new approaches to pneumococcal 
vaccine development and consideration of other cellular components as vaccines.  
Considerable research is being conducted on potential third-generation common 
protein vaccines. Candidates under consideration include PsaA and a recombinant 
nontoxic pneumolysin (Ply) amongst others (37, 77). These pneumococcal proteins, 
which are T cell dependent, appear to be common to all pneumococcal serotypes and are 
likely to be highly immunogenic in humans and to elicit immunologic memory (37). In 
contrast to current pneumococcal vaccines, third-generation vaccine candidates will 
provide protection to a broader target population, from infants to elderly individuals and 
those at high risk. Furthermore, it is hoped that these will not be geographically specific 
and will provide protection against all pneumococcal serotypes. Another advantage is that 
 10
the new vaccines could be produced in large quantities at low cost with recombinant 
technology in an appropriate host such as E.coli (77). 
The increase in pneumococcal antibiotic resistance has further complicated the 
problem. The serotypes 6B, 9V, 14, 19A, 19F, and 23F cause most drug-resistant 
infections in the United States (36). In some areas, 35%-50% of pneumococcal isolates 
are resistant to penicillin. Many of these isolates are also resistant to other antimicrobial 
drugs, with some isolates susceptible only to vancomycin. Recently though, vancomycin 
tolerance emerged in pneumococci (36). This reinforces the need for an effective 
improved vaccine and/or effective new drugs against pneumococcal infections. 
Although S. pneumoniae is the most common bacterial cause of pneumonia in 
children and adults worldwide, the diagnosis of pneumococcal pneumonia is difficult to 
establish. Blood cultures are positive in only 20%-30% of adults and less than 10% in 
children with pneumococcal pneumonia (10, 70). Sputum is also difficult to obtain and 
young children do not produce sputum. Further more, sampling via bronchioscope is 
laborious.  
Other specialized tests for characterization of S. pneumoniae include PCR. The 
genes that have been targeted are the genes encoding pneumolysin, autolysin, and 
pneumococcal surface protein (69). Salo et al, initially developed a PCR assay for the 
etiologic diagnosis of pneumococcal pneumonia. They targeted the pneumolysin gene 
and used nested PCR to amplify a 348-bp and a 208-bp fragment of the gene (70). Nested 
PCR means that two pairs of PCR primers were used for a single locus. The first pair 
amplifies the locus as seen in any PCR experiment. The second pair of primers (nested 
primers) bind within the first PCR product and results in a second PCR product that will 
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be shorter than the first one. The logic behind this strategy is that if the wrong locus were 
amplified by mistake, the probability is very low that it would also be amplified a second 
time by a second pair of primers. The initial PCR assay developed by Salo et al was 
prone to contamination problem and was further modified. The modification was based 
on the amplification of a 209-bp segment of the pneumolysin gene. For demonstration of 
the amplification product, microwell hybridization with a Europium-labeled 
oligonucleotide probe complementary to a biotinylated strand of the PCR product was 
performed, and the presence of the PCR product was monitored by time-resolved 
fluorescence of the Europium chelate (69). This modified assay proved to be reliable and 
is suitable for automation therefore can be used to test high numbers of samples. 
Several PCR methods for identification of S. pneumonia have been developed by 
Dr. Facklam’s group at the CDC (37, 54, 55, 61). They targeted the gene encoding  
pneumococcal surface antigen adhesin A (PsaA). An 838-bp fragment of the gene was 
amplified in all strains tested. This PCR assay has by far been the most powerful assay 
developed for detection of S. pneumoniae for several reasons. First, they demonstration 
of psaA in all pneumococcal serotypes . This has clinical significance because of the 
potential to design assays to detect all S. pneumoniae isolates regardless of serotype. 
Second, this Assay also showed lack of amplification of heterologous organisms 
suggesting that this could be a useful tool for detection of pneumococci in clinical 





Chemotherapy and Management of S. pneumoniae Infections 
Treatment and management of S. pneumoniae infections currently focus on 
antimicrobial agents and vaccines (described above). Several different groups of 
antimicrobial agents are used to treat S.  pneumoniae infections. By far the most common 
agents are the β-lactam antibiotics which include Penicillins, Cephalosporins (Figure 1), 
Monobactams and Carbapenems. β-lactams act by inhibiting bacterial cell wall synthesis. 
Vancomycin though not considered a β-lactam antibiotic, also prevents cell wall 
synthesis. Another group of antimicrobial agents used to treat S. pneumoniae infections 
are Macrolides such as Erythromycin. These act by binding free ribosomes thus 
preventing protein synthesis. Sulfonamides such as sulfamethazole act by preventing the 
synthesis of bacterial folic acid (31). Fluoroquinolones are also used, and these bind to 




Figure 1: Diagram of Penicillin and Cephalosporin, modified from (67) 
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The β-lactams are by far the most widely used and efficacious of all antibiotics. 
The current choice of treatment of pneumococcal infections are β-lactams such as, 
amoxicillin (a penicillin derivative). β-lactam antibiotics prevent cell wall synthesis by 
targeting transpeptidases (33).  
The cell wall of bacteria is a peptidoglycan (murein) layer composed of two sugar 
derivatives, (N-acetylglucosamine and N-acetylmuramic acid) and a small group of 
amino acids (Figure 2). Synthesis of peptidoglycan during cell growth involves controlled 
cutting by autolysins of bonds connecting small areas of preexisting peptidoglycan, with 
the simultaneous insertion of new pieces of peptidoglycan. The final step in cell wall 
synthesis is formation of the peptide cross-links between adjacent glycan chains. This is 
the step catalyzed by transpeptidase (also known as penicillin-binding proteins). 
Inhibition of the transpeptidation step by β-lactam antibiotics thus leads to the formation 




Figure 2: Schematic Section of Bacterial Peptidogylcan layer, modified from (67) 
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Antibiotic Resistance 
Antibiotic resistance has become a disturbing problem in the medical community. 
For many years after the introduction of penicillin, commonly encountered gram-positive 
bacterial pathogens were susceptible to this and other relatively simple antibiotics. 
However, spontaneous mutation or the acquisition of genetic determinants conferring 
antibiotic resistance and selection of these resistant bacterial strains occurred fairly 
quickly (46). S. pneumoniae was formerly uniformly susceptible to penicillin, but as early 
as 1960, strains resistant to penicillin were reported. Unfortunately, penicillin-resistant 
pneumococci tend to be resistant to other antibiotic classes as well, notably the 
sulfonamides, tetracyclines, macrolides, clindamycin and chloramphenicol (46).  
Currently, the most effective antibiotics against penicillin-resistant pneumococcal 
strains are vancomycin and certain of the newest fluoroquinolones. However, 
vancomycin must be administered intravenously to treat pneumococcal infections and its 
use tends to select for vancomycin-resistant Enterococci. The fluoroquinolones have 
drawbacks due to the ease of acquiring resistance by changing only one nucleotide in the 
DNA gyrase and relatively expensive (46). Thus, the evolution of frequent, high-level 
penicillin resistance in the pneumococcus has led to a reappraisal of the treatment of 
common respiratory tract infections. This includes a greater emphasis on routine 
susceptibility testing of pneumococcal clinical isolates, increased efforts to detect 
resistance in pneumococci, and use of the recently developed protein-polysaccharide 




Antibiotic Resistance Mechanisms: β-Lactamases 
Among Otitis media pathogens, the simplest mechanism of resistance is the 
production of β-lactamases (27). β-Lactamases are a group of microbial enzymes 
belonging to several classes that all function by cleaving the β-lactam ring of these 
antibiotics, thus inactivating them. As these enzymes are frequently plasmid encoded, 
resistance can readily be transmitted between bacteria. S. pneumoniae is naturally 
competent for genetic transformation. This competence in S. pneumoniae is regulated by 
a quorum-sensing system (45). Despite the fact that pneumococci are naturally 
transformable, current researchers state that no β-lactamase producing strain has been 
described (27). Microorganisms such Haemophilus influenzae and Moraxella catarrhalis 
in combination with S. pneumoniae cause respiratory tract infections and Otitis Media; 
yet both of those strains possess β-lactamases. Since S. pneumoniae is a natural 
transformant, it would seem probable that they would also possess β-lactamase genes. 
This however has not been widely studied. Due to the absence of β-lactamases, 
penicillin-resistant pneumococci are not susceptible to combination drugs such as 
amoxicillin-clavulanate and ampicillin-sulbactam which contain β-lactamase inhibitors 
(46).  
 
Antibiotic Resistance Mechanisms: Altered Penicillin-Binding Proteins 
Evidence from studies on laboratory isolates of penicillin-resistant pneumococci 
and on the genetic transformation of resistance has indicated that penicillin resistance is a 
multigenic property acquired in a stepwise fashion (28). It was established that resistance 
is associated with alterations in the penicillin –binding proteins (PBPs) that catalyze the 
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terminal steps in the assembly of the bacterial cell wall and are the targets of β-lactam 
antibiotics (28). 
Early studies using radioactively labeled penicillins incubated with isolated 
bacterial membranes subjected to SDS-PAGE analysis showed that S. pneumoniae had 3 
major groups of penicillin-binding proteins named PBPs 1, 2, and 3 (12, 65). 
Comparisons of susceptible strains and resistant strains revealed that resistant bacteria 
retain a normal set of PBPs, but one or more of these appear to have lower binding 
capacity for the antibiotic than the same PBPs from susceptible cells (26, 65). In order to 
establish the nature and properties of these PBPs, studies were conducted with the 
proteolysis of the PBPs. Results indicated that the β-lactam binding sites of the PBPs 
were similar. The PBPs were also converted into soluble, hydrophilic derivates indicating 
that they were membrane bound (21). Immunological studies using antibodies prepared 
against the penicillin-susceptible PBPs indicated that the resistant strains had PBPs that 
were immunologically related to the susceptible PBPs with the difference being only in 
the binding affinity to β-lactams (26). 
 To date it has been established that S. pneumoniae contain six PBPs which are 
classified into two group mainly based on their molecular sizes (96). Group I consists of 
the low-molecular-mass PBPs. These exhibit DD -Carboxypeptidase activity, removing 
the C-terminal D-alanine of the pentapeptide side chain in the murein (71). They appear 
to be important but non-essential for cell growth (42, 96). In S. pneumoniae this is 
represented by PBP3 (43 kDa). This protein has been proposed to be dispensable, since a 
variety of β-lactams are bound by PBP3 far below their respective MICs and since the 
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penicillin affinity of PBP3 is not altered in intrinsically penicillin-resistant strains (42, 
71).  
 Group II PBPs are the high-molecular-mass PBPS. Unlike the low-molecular-
mass PBPs, these are essential (96). These possess essential transpeptidase (cross-linking) 
and transglycosylase (elongation) activities responsible for bacterial cell wall 
peptidoglycan synthesis (33). The transpeptidase activity of these PBPs is inhibited by β-
lactam antibiotics.  
 
Table 1:  Summary of S. pneumoniae Penicillin-Binding Proteins 
 
PBP Molecular Mass 
 
Importance in Resistance Development 
*PBP 1a 98 kDa Required for high level β-lactam resistance. 
PBP 1b 89 kDa Role not established 
*PBP 2x 82 kDa Primary resistance determinants and confer low- level β-
lactam resistance. Prerequisite for high resistance 
PBP 2a 81 kDa Some low affinity forms have been found 
*PBP 2b 77 kDa Primary resistance determinants and confer low- level β-
lactam resistance. But does not interact with expanded-
spectrum cephalosporins. 
PBP 3 43 kDa Does not participate in resistance development 
 
* PBPs found to be altered in high level resistant isolates. The above table is summarized 
from Hakenbeck et al (26, 27) and Laible et al (43). 
 
 
The high-molecular-mass PBPs have been subdivided into class A and class B, 
which differ in part by sequences of the N-terminal regions (33). In S. pneumoniae, class 
A PBPs are represented by PBP1a (98 kDa), PBP1b (89kDa), and PBP2a (81kDa), and 
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class B PBPs are represented by PBP2x (82 kDa) and PBP2b (77 kDa) (21, 33). The C-
terminal domains of both classes appear to possess transpeptidase activity. The functions 
of the N-terminal domains are less established, but for class A high-molecular-mass PBPs 
evidence suggests that they possess transglycosylase activity (33). The N-terminal 
domains of the class A PBPs contain four conserved motifs that are also present in 
monofunctional transglycocylases, and several of the class A proteins have been shown 
to catalyze the polymerization of the polysaccharide backbone of peptidoglycan in vitro 
(33). 
The structure of a penicillin-binding protein, a soluble derivative of S. 
pneumoniae PBP2x, has recently been determined by X-ray crystallography (63). It 
consists of three domains: an N-terminal domain with the appearance of a ‘sugar-tongue’ 
that is in close association with a second, central penicillin-binding domain, and a C-
terminal domain that is connected via 28-residue-long flexible loop. The penicillin-
binding domain which is homologous to that of other PBPs and β-lactamases, contains 
three conserved amino acid motifs that are in a close spatial relationship as part of the 
active site of the enzyme (27). PBPs interact with β-lactams by forming a relatively 
stable covalent complex via the active site serine nucleophile. Eventually, deacylation of 
this complex takes place, resulting in a biologically inactive β-lactam derivative.  
Mutations that contribute to resistance are located in the transpeptidase-penicillin 
binding domain and they reduce the affinity to β-lactams rather than affecting the 
deacylation step (27). Several mutations in one PBP may be required to cause a 
substantial decrease in penicillin-binding affinity, and more than one PBP may have to be 
changed into low-affinity variants in order to achieve high resistance levels. In S. 
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pneumoniae, alterations in the PBP1a, PBP2x, and PBP2b confer low resistance and are 
the prerequisite for high levels of resistance mediated by mutations in other PBPs (25, 
50).To date, sequences of S. pneumoniae PBPs from several susceptible and resistant 
strains are known and are available through GeneBank. 
 There has been extensive research done on S. pneumoniae PBPs but there are still 
however some areas that need more studies. For example, the role of some of the high-
molecular-mass PBPs such as PBP1b and PBP2a is vague. It has also been established 
that the low-molecular-mass PBP3 does not play a role in resistance development. 
However there have been occasions where resistant strains have been isolated that 
exhibited a higher than normal molecular weight but the reasons behind these 
observations have not been fully explored. PBP2x has also been shown to be a 
prerequisite for high resistance to β-lactams. It has not yet however been determined 
which of the many substitutions in the PBP2x gene contribute to the greatly decreased 
affinity of PBP2x for β-lactams (43).  
Recently, a third level of resistance mechanisms has been identified in laboratory 
mutants, wherein non-PBP genes are mutated and resistance development is accompanied 
by deficiency in genetic transformation (27). Two such non-PBP genes have been 
described: a putative glycosyltransferase, CpoA, and a histidine protein kinase, CiaH. It 
has been proposed that these non-PBP genes are involved in the biosynthesis of cell wall 
components at a step prior to the biosynthetic functions of PBPs, and that the mutations 
selected during β-lactam treatment counteract the effects caused by the inhibition of 
penicillin-binding proteins (27). This mechanism of resistance is however still under 
investigation. 
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 Other mechanisms of resistance directed towards non-ß-lactam drugs used to treat 
S. pneumoniae infections may include production of adenine dimethylase, which acts on 
the 23S ribosomal RNA to reduce macrolide binding to the ribosome (31). Resistance to 
sulfonamides may involve mutations in target enzymes responsible for folic acid 
biosynthesis, and resistance to Fluoroquinolones may also involve mutations in DNA 
gyrase genes, preventing binding to DNA gyrase (31). 
 
The Role of Horizontal Gene Transfer in Development of S. pneumoniae Altered 
Penicillin-Binding Proteins 
 
Gene transfer among bacteria may occur by either of three processes: (i) 
Conjugation, a process that requires cell-to-cell contact, (ii) Transduction, a process that 
is mediated by a bacteriophage, and (iii) Transformation, a process in which a recipient 
cell acquires plasmids or free (extracellular) fragments of DNA from its surroundings, 
and subsequently incorporates such fragments into its chromosomal DNA. 
The mechanism of natural genetic transformation by bacteria is described in a 
review by Lorenz and Wackernagel (48). These authors describe natural gene 
transformation to distinguish it from in vitro (artificial) procedures used to introduce 
DNA molecules into bacterial cells. Bacteria are the only organisms capable of natural 
genetic transformation. S. pneumoniae is historically known for its ability to carry out the 
process of natural gene transformation. The process of natural gene transformation only 
occurs during a specific period in the exponential growth phase when cells are in a state 
of competence. The state of competence develops suddenly in response to cell-to-cell 
signals, and its duration is approximately 20 minutes. Lee and Morrison (45, 89) 
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identified several genes in S. pneumoniae that regulated competence, and linked quorum 
sensing to the development of competence for natural genetic transformation. 
Naturally transformable organisms such as S. pneumoniae have ready access to a 
wide pool of genetic diversity from closely related species, and it is the frequency with 
which advantageous genes can be shuffled that has resulted in these organisms becoming 
resistant to antibiotics in a period of less than 30 years (20). Perhaps the best recorded 
examples of mosaic genes related to antibiotic resistance that have arisen from 
interspecies recombination are the altered penicillin-binding proteins (PBPs) in 
Streptococcus and Neisseria (50). The large-scale use of antibiotics has created a 
selection pressure that has promoted the spread of mosaic genes encoding proteins with 
decreased affinity for at least two important classes of antimicrobial agents: the ß-lactams 
and the sulfonamides. 
Genetic analysis of genes encoding PBPs concluded that these mosaic genes were 
the result of localized recombination events between S. pneumoniae and the homologous 
genes from Streptococcus mitis and Streptococcus oralis (20). These organisms are 
commensal members of the oral flora. As these bacteria coexist within the oral cavity it is 
quite feasible that there is a complex network of interspecies gene transfer (90). It has 
been shown that to be resistant to penicillins, a pneumococcus must acquire low-affinity 
variants of three PBPs (PBPs 1a, 2b, and 2x). The accumulation of three separate 
penicillin-resistant PBPs encoded by mosaic genes seems at first sight unlikely, but 
nucleotide sequence data show that this has occurred on many separate occasions, leading 
to the widespread penicillin resistance observed in the pneumococcus. Moreover, in S. 
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pneumoniae pbp1a and pbp2x are cotransformable, by virtue of their proximity on the 
chromosome. This resistance hence has the potential for rapid spread among strains (50). 
Genetic studies comparing sequences of pbp2x in some susceptible and resistant 
strains strongly suggests that the altered PBP2x genes have arisen by localized 
interspecies recombinational events. One particular study by Laible et al (43), showed 
that in a 2kb region, the susceptible S. pneumoniae clinical isolates differed at only 8 
nucleotide sites (0.4%) and resulted in one single amino acid difference in PBP2x. In 
contrast, the sequences of the PBP2x genes from the resistant isolates differed overall 
from those of the susceptible isolates between 7 and 18% of nucleotide sites and resulted 
in between 27 and 86 amino acid substitutions in PBP2x. The altered PBP2x genes 
consisted of regions that were similar to those of susceptible strains (< 3% diverged), 
alternating with regions that were very different (18-23% diverged). The presence of 
highly diverged regions within the PBP 2x genes of the resistant isolates contrasted with 
the uniformity of the sequences of the amylomaltase genes from the same isolates, and 
with the uniformity of the PBP2x genes in the susceptible isolates. 
 More recently, the emergence of multidrug-resistant S. pneumoniae variants are 
thought to arise through natural transformation involving recombinational replacements, 
within and around the capsule biosynthesis (cps) locus, of DNA fragments sometimes as 
large as 25 kb (17). The cps locus of S. pneumoniae is flanked by the pbp2x and pbp1a 
genes coding for penicillin-binding proteins, enzymes involved in the cell wall synthesis 




Natural Transformation in S. pneumoniae 
The term “natural genetic transformation” has been coined to distinguish it from 
other (artificial) in vitro procedures used to introduce DNA molecules into bacterial cells 
(48). 
The first evidence of bacterial transformation was obtained by British scientist 
Fred Griffith in the late 1920s. Griffith was working with S. pneumoniae, a bacteria that 
invades the body with the help of a polysaccharide capsule. Griffith discovered that 
isolates lacking the capsule (formed R- rough colonies) were unable to cause infection 
when injected to a mouse. A mouse infected with the capsule strain (formed S- smooth 
colonies) would cause infection in a day or two. Griffith showed that if heat killed S cells 
were injected along with R cells, there was a fatal infection, and the bacteria isolated 
from the dead mouse were S type. This meant that the R cells had been transformed to a 
new type. The molecular explanation for the transformation was later provided by 
Oswald T. Avery and colleagues in the 1930s. They were able to conduct the same 
transformation in a test tube. After fractionating, they purified the active fraction of cell-
free extracts and showed it to consist of DNA.  
 Competence for transformation in Streptococci is not constitutive, as it is in 
Neisseria species, but is regulated by a quorum-sensing system encoded by two genetic 
loci, comCDE and comAB (45, 89). The com operon contains three genes comC, comD 
and ComE, encoding a competence-stimulating peptide (CSP), histidine kinase, and a 
response regulator respectively (45, 89). Two genes located elsewhere on the 
chromosome, comA and comB, encode proteins responsible for the export of CSP from 
the cell (89). CSP induces competence when a critical extracellular concentration is 
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reached. The comD-encoded transmembrane histidine kinase is believed to be a receptor 
for CSP and to phosphorylate a comE-encoded transcription regulator, producing an 
active form that up regulates both the comCDE operon and, a number of other genes 
involved in competence development (45, 89). 
 Tomasz and Hotchkiss were two pioneers that paved the way to understanding 
natural transformation in S. pneumoniae. Their studies involved the use of an 
unencapsulated pneumococcal culture Avery R36A strain, subline R6 (34, 81-83) which 
is still being used by most scientists studying S. pneumoniae to date.  
It was first thought that the ability of S. pneumoniae to react with DNA was a 
result of a mutation or a terminal change undergone by certain abnormal cells (34). It was 
demonstrated by Hotchkiss in 1954 that this ability to react to DNA is a physiological 
property. He demonstrated this by growing a culture of R36A strain and periodically 
taking samples to expose to DNA for 5 min from a single high-step mutant strain 
resistant to streptomycin. Exposure to DNA after 5 min was terminated by addition of 
DNase. The number of transformants produced were scored by growing in medium 
containing streptomycin. Results indicated that after about 3 1/2- 4 hrs of growth, a 
fraction of the population respond to the DNA and become transformed to resistant cells.  
Later Tomasz and Hotchkiss in 1964, demonstrated that the regulation of 
transformability of pneumococcal cultures were by a macromolecular cell products. They 
grew two sets of cell. One culture was taken at a competent state (the activator culture) 
and the other culture was an incompetent culture (detector culture). They found that 
inoculation of the activator (competent) culture into the detector (incompetent culture) 
would transfer competence from the activator to the detector cultures. The cultures were 
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tested for competence by the method described above. To further study this, Tomasz in 
1965 set up a similar set of experiments only this time the two cultures were introduced 
into the separate compartments of a U-shaped glass tube which was divided by a 
Millipore membrane. This prevented physical contact between the competent and 
incompetent bacteria. Results indicated that competence was still transferred and that this 
cell-to-cell transfer of competence did not necessarily require physical contact of the 
organisms. The activator substance was afterwards isolated from the competent 
pneumococci (81). It was found that purified preparations of this heat-labile material 
could convert incompetent bacteria to competence in a fast reaction, the rate depending 
on the concentration of both the activator and the cell (81). This activator material is what 
is referred to now as the competence stimulating peptide (CSP) and can be synthetically 
generated.  
 Even though the activator material responsible for S. pneumoniae competence had 
been discovered, natural competence was not easily demonstrated nor easily 
reproducible. There seemed to be several factors affecting development of competence. 
Some of which were environmental and some cellular. These factors also appear to vary 
from strain to strain. 
 
Common Factors Affecting S. pneumoniae Natural Transformation 
i.) Cell density. Tomasz in 1965 demonstrated that the time needed to reach a 
maximal frequency of competence in a growing culture was found to be a roughly inverse 
function of the cell concentration (81). It was found that the delay in the expression of 
competence could be considerably shortened if dilute cultures of pneumococcal were 
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concentrated to a higher cell density. Different inocula sizes (104 – 106) were used and at 
frequent intervals, samples were taken and tested for competence using the methods 
described above. To date competence in S. pneumoniae has been demonstrated at 
densities ranging from 106 – 108 (23, 64). It has been suggested that in the natural 
environment (the nasopharynx) this could be important because if the cell density critical 
for competence is close to that which triggers host defenses, competence could then serve 
for adaptation of S. pneumoniae to host defense-generated stress (15). 
ii.) pH. In S. pneumoniae, an increase of the pH of the medium continuously 
moved the competence peak to earlier exponential phase and thus to lower cell densities 
(48). A slightly basic pH seems to be optimal (7.4 to 8.0) and no competence is detected 
at pH less than 7.0 (23, 48, 49, 81, 83). The reason being that the CSP is more active at 
alkaline than neutral pH (48). 
iii.) Calcium. In S. pneumoniae Ca2+ is essential for growth, competence 
development, and autolysis (48, 49). Competence is induced optimally at 1 mM Ca2+. 
Genetic evidence for a Ca2+ transporter, mediating the Ca2+- dependent development of 
competence, came from studies with a mutant which was nontransformable (and resistant 
to autolysis) in high- Ca2+ medium and which was resistant to a specific inhibitor of 
calcium transporter, 2’, 4’ –dimethylbenzamil (48). It has been suggested that induction 
of competence is a response to stress produced by high concentrations of Ca2+ (1 mM), 
which may prevail in the natural environment of S. pneumoniae, the body fluids. 
iv.) Albumin (either as purified fraction BSA or as heat-inactivated serum). It was 
established by Hotchkiss and Tomasz in their pioneering work that serum albumin was 
required for S. pneumoniae natural transformation (34, 81). To date, the addition of 
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serum has been maintained in transformation experiments (4, 29, 57-59). It has also been 
stated in a review article on cloning and expression of pneumococcal genes that  “serum 
albumin must be added to all transformation media” (40). It has been suggested that 
albumin may function to stabilize or limit the absorption of certain competence factors to 
in vitro surfaces (49). 
v.) Oxygen. Oxygen availability is a major determinant for competence 
development in exponentially growing cultures of S. pneumoniae (14). It is known that 
NADH oxidase activity is required for optimal competence in cultures grown aerobically 
but the exact role of oxidative metabolism in competence regulation is still under 
investigation (14). 
vi.) Capsule. Although transformation has long been described as a characteristic 
of the pneumococci, most studies involving this process have focused on a few laboratory 
strains, mainly descended from a single unencapsulated subclone (R36A), for which 
optimal media and protocols were developed (8, 66). All successful natural 
transformation experiments (that is, without addition of exogenous CSP) to date have 
been conducted with unencapsulated strains (8, 48, 52, 66). In contrast, strains of clinical 
importance are encapsulated since the capsule is a major virulence factor. The presence 
of capsule abolishes competence for natural genetic transformation (8, 48, 66). Several 
surveys conducted with a collection of clinical isolates of virulent, encapsulated S. 
pneumoniae showed them to all be nontransformable (48, 66). However, some of these 
isolates developed competence when induced by exogenously added competence factor 
of a highly transformable laboratory strains.  
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In depth studies were done on 42 encapsulated strains by one group of scientists 
using the competence stimulating peptides derived from two different unencapsulated 
strains (CSP-1 and CSP-2). These CSPs have been previously studied and shown to differ 
in their comC genes (66). These two genes are widely distributed in S. pneumoniae. First, 
the nucleotide sequence of comC  in each strain was determined for both strands. The 
allele comC2 was found in 12 strains, while comC1 was present in the other strains. The 
synthetic peptides (CSP-1 and CSP-2) were used to induce competence in the 42 strains. 
22 of the 42 (48%) became competent after addition of the CSPs, but none of the strains 
were competent in parallel cultures without added peptide. Two of the strains responded 
to both CSP-1 and CSP-2, while each of the others that became competent responded 
only to the pheromone encoded by its own comC allele. 
Several reasons have been suggested for nontransformability of natural isolates: 
(i) the presence of the capsule, which may constitute a physical barrier for the excretion 
and penetration of the produced competence factor; (ii) the presence of a defect in the 
production or excretion of the competence factor in some strains; and (iii) a defect in the 
DNA-processing machinery in strains which were nontransformable even with 
exogenously added competence factor (48). 
 
Genetic Manipulations of S. pneumoniae 
 The information provided by genomic sequencing has heightened expectations of 
solutions to biological networks. This cannot however be solved by genomic analysis 
alone. It is necessary to combine genomic analysis with traditional genetic manipulation. 
The genetic manipulation of S. pneumoniae is made easier because it is a natural 
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transformant. Studies have shown that by just mixing cloned pbp1a and pbp2x genes 
from resistant strains with naturally competent susceptible strains can transform the 
susceptible strains to the full level of the antibiotic resistance (16).  
Several genetic transfer vectors have been described for use in S. pneumoniae 
such as the E.coli – Streptococcus shuttle vector, pDP28 and pJDC9 (3, 74, 88). An 
example of a specific genetic system that has been used to generate a better 
understanding of resistant mechanisms by Weber et al, 2000. The study investigated the 
function of the fib locus (factor important for bet-lactam resistance). The fib locus was 
discovered by using homology sequences to femAB operon of S. aureus. In S. aureus, 
several genetic loci called fem are essential for the expression of methicillin resistance, 
and insertional inactivation of femA and femB completely abolishes ß-lactam resistance. 
Weber et al, found two genes with homology to S. aureus femA/B in the S. pneumoniae 
genome sequence, named fibA and fibB. In order to investigate the function of the fib 
locus, loss-of-function mutants were constructed by insertion-duplication mutagenesis, 
using the plasmid pJDC9. The plasmid cannot replicate in S. pneumoniae, but contains an 
erythromycin resistance gene selectable in this organism. An internal gene fragment of 
fibA was cloned into pJDC9 and transformed into S. pneumoniae. Erythromycin-resistant 
transformants were readily obtained; integration of the plasmid into the chromosome by 
homologous recombination via the inserted fibA gene fragment, and hence disruption of 
fibA, was verified by PCR analysis of the transformants. In all ß-lactam-resistant 
transformants, disruption of the same fib locus resulted in an extreme reduction of the 
resistance phenotype. 
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One of the most important developments in S. pneumoniae genetic manipulations 
came recently with the development of intergrational plasmids for the tetracycline-
regulated expression of genes in S. pneumoniae (78). This was based on gene knock-out 
technologies which are commonly used to determine the essentiality of a given protein 
for bacterial growth and survival. If an essential gene is disrupted, no viable bacterial 
cells are obtained. This is only negative evidence. In order to obtain positive indications 
for the essentiality of a given gene, Stieger et al developed this controllable knock-out 
system. Plasmids were designed that allow fusion of a tetracycline controllable promoter 
to any gene of choice on the streptococcal chromosome (78). The usefulness of the 
system was demonstrated by the tetracycline-regulated production of firefly luciferase in 
S. pneumoniae, which can be induced fivefold by the addition of tetracycline. By using 
two promoters of different strength and depending on the presence or absence of 
tetracycline, an 80-fold range of luciferase activities can be covered. The system was also 
used to construct strains that depend on the addition of tetracycline for the production of 
the A subunit of DNA gyrase, an essential streptococcal protein. The growth of such a 
strain depends on the addition of tetracycline to the medium. In the absence of 
tetracycline, the cells cease to grow and are not viable. The system presented by Stieger 
et al, should be useful for the characterization of gene networks in S. pneumoniae.  
 
S. pneumoniae Genome 
To date, there are three S. pneumoniae genomes that have been sequenced 
completely and are publicly available. The genomes are from different strains namely; a 
19F strain sequenced by Glaxo-SmithKline, a type 4 strain sequenced by TIGR and strain 
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R6 by Eli Lilly (13).  Strain R6 is a descendant of the type 2 capsule clinical isolate used 
by Avery and coworkers to demonstrate the genetic function of DNA, and it is used 
worldwide as a standard laboratory strain.  
The R6 strain was reported to be 2,038,615 bp and 40% G + C content. It contains 
2, 043 predicted protein coding regions and 73 noncoding RNA genes (32). As a 
consequence of the capacity of S. pneumoniae to take up DNA, its genome is littered with 
genes that are apparently derived from other bacteria. There are 40 ORFs that are similar 
to genes in gram-negative bacteria and that have not been found in other gram-positive 
genome sequences (32). This is not surprising, because S. pneumoniae occupies the same 
niche in the human respiratory system as several gram-negative species such as 
Haemophilus influenzae. Additionally, at least 2% of the genes were found to be 
significantly truncated relative to orthologous genes characterized in other bacteria. 
Transporters are the most frequently truncated genes and it was shown that there are five 
ORFs that are similar to genes encoding drug efflux pumps (32). 
The virulent isolate sequenced by TIGR was shown to have 2,160,837 base pairs 
with G + C content of 39.7%. It contains 2236 predicated coding regions; of these, 1140 
(64%) were assigned a biological role (79). 
Glaxo-SmithKline presented sequences and functional annotations for the 2.1 













Strain R6  

































 The emerging levels of antibiotic resistance exhibited by S. pneumoniae strains 
has become a serious concern for the medical community hence the establishment of the 
Pneumococcal Molecular Epidemiology Network (PMEN). This network was established 
in 1997 under the auspices of the International union of Microbiological Societies with 
the aim of standardizing the nomenclature and classification of resistant pneumococcal 
clones worldwide. Specific objectives of the network include the following; international 
collaborations and training support between laboratories and institutions; increased 
knowledge of resistance and spread of pneumococcal worldwide; standardization of 
nomenclature of national and international clones; identification of clones using pulse-
field gel electrophoresis (PFGE), BOX-PCR, and multilocus sequence typing (MLST); 
availability of reference isolates of each clone from the American Type Culture (ATCC) 
Collection, and access to information through a website (53). 
 
 The first phase of my research focused on two hypotheses: 
 
1. We hypothesize that resistant strains of S. pneumoniae exhibit altered penicillin- 
binding proteins (PBPs) that differ from PBPs in susceptible strains, as a 
mechanism of resistance to β-lactam antibiotics.  
To test this hypothesis, we propose to determine susceptibility patterns of all clinical 
isolates to different β-lactam antibiotics. We also propose to study membrane fractions of 
any highly resistant strains to determine if any proteins correlate with resistant associated 
PBPs based on their molecular masses and peptide sequences.  
 
2. We hypothesize that S. pneumoniae strains may express different protein 
molecules in their cell envelope that function as virulence factors and/or 
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epidemiological markers that could be used to distinguish between different 
clones.  
To test this hypothesis, we propose to use SDS-PAGE to generate whole cell protein 
profiles of all our strains to determine similarities and differences in protein patterns 
among strains.  
 
Data generated from the initial characterization of 17 S. pneumoniae clinical isolates, 
showed that one strain (Sp D2) exhibited high level resistance to β-lactam antibiotics and 
also expressed a unique membrane-bound protein in 1D-SDS-PAGE gels. Then the 
membrane fraction was isolated and further analyzed by MALDI-MS analysis and 
Edman degradation sequencing. The resulting peptide mass fingerprints and amino acid 
sequences did not produce any significant matches when searched against all available 
sequence data, which included the published S. pneumoniae genomes. This led to 
collaborations with Dr. Richard Facklam of the Division of Bacterial and Mycotic 
Diseases, National Center for Infectious Diseases, CDC, to further characterize Sp D2 
and determine if it exhibits criteria established for typical S. pneumoniae.  
 
3. We hypothesize that Sp D2 may express genes that encode for a pneumococcal 
capsular serotype that is atypical, and that this strain may contain genes that 
encode for other virulence factors, or that this strain may be incorrectly classified. 
     To test these hypotheses, we propose to further characterize all strains by serotyping 
using the antipneumococcal capsular antibodies and use PCR assays to analyze all strains 
for the presence of the following genes: the PsaA that encodes for the pneumococcal 










MATERIALS AND METHODS 
 
Growth Conditions and Storage of Test Organisms 
 All organisms used in this study are listed in Table 4. Stock cultures of all strains 
were maintained in Mueller Hinton broth plus 15% glycerol and stored in a Revco freezer 
at –800C and sub-cultures of working stock were stored for short periods of time at  –
200C. Organisms were grown on Mueller-Hinton agar (Difco) supplemented with 5% 
defibrinated sheep blood (Remel). For broth cultures, the strains were grown on liquid 
media containing BHI (Difco) supplemented with 0.2 % yeast extract (Difco) and 5% 
casein (Difco) Cultures were incubated at 370C and 5% CO2 in a water-jacketed 
incubator or in a candle jar. Prior to each experiment, purity of the strains were 
determined by streaking on Mueller-Hinton agar supplemented with 5% defibrinated 
sheep blood and observed for the characteristic alpha-hemolysis. In addition, Gram stains 









Table 3: Streptococcus pneumoniae Test Strains 
Organism Strain Source 
Sp 83 Vaccine strain CDC, Atlanta, GA 
Sp 86 Vaccine strain CDC, Atlanta, GA 
Sp 95 Vaccine strain CDC, Atlanta, GA 
Sp 105 Vaccine strain CDC, Atlanta, GA 
Sp 117 Vaccine strain CDC, Atlanta, GA 
Sp 125 Vaccine strain CDC, Atlanta, GA 
Sp D1 Clinical isolate Duke University, NC 
Sp D2  Clinical isolate Duke University, NC 
Sp D3 Clinical isolate Duke University, NC 
Sp D4 Clinical isolate Duke University, NC 
Sp D5 Clinical isolate Duke University, NC 
Sp D6 Clinical isolate Duke University, NC 
Sp D7  Clinical isolate Duke University, NC 
Sp D8 Clinical isolate Duke University, NC 
Sp D9 Clinical isolate Duke University, NC 
Sp D10 Clinical isolate Duke University, NC 
Sp D11 Clinical isolate Duke University, NC 
Sp D12 Clinical isolate Duke University, NC 
Sp G-25053 Clinical isolate Grady Hospital, Atlanta, GA 
Sp G-31159 Clinical isolate Grady Hospital, Atlanta, GA 
Sp G-5481 Clinical isolate Grady Hospital, Atlanta, GA 
Sp G-31483a Clinical isolate Grady Hospital, Atlanta, GA 







Kirby-Bauer Susceptibility Tests 
 All strains were tested for susceptibility to β-lactams (ampicillin, ceftazidime and 
amoxicillin) and a glycopeptide (vancomycin) using the Kirby-Bauer test (Dispens-O-
Disc). The antibiotics were obtained from a commercial source (Difco; Becton 
Dickinson). S. pneumoniae cultures were grown on Mueller-Hinton agar supplemented 
with 5% defibrinated sheep blood overnight. Several colonies were taken from these 
plates using sterile cotton swabs, suspended in sterile BHI supplemented with yeast 
extract and casein. The turbidity was adjusted comparable to a 0.5 McFarland standard 
using a spectrophotometer 20. A sterile cotton swab was used to inoculate the entire 
surface of several blood agar plates with the standardized culture to produce a confluent 
lawn of growth on the plate. Antibiotic disks were placed aseptically on the plates. Plates 
were incubated overnight in an atmosphere of 5% CO2. Diameter of zones of growth 
inhibition were measured in millimeters and compared to breakpoint numbers in the 
manufacturer’s interpretive standards. Strains were categorized as susceptible, 
intermediate, or resistant to each antibiotic tested. 
 
Minimum Inhibitory Concentration (MIC) Test 
The MIC procedure for testing susceptibilities to penicillin G, ampicillin and 
amoxicillin was performed according to the NCCLS (National Committee for Clinical 
Laboratory Standards). 
 i.) Preparation of Organisms. Each S. pneumoniae strain was grown on Mueller-
Hinton agar supplemented with 5% defibrinated sheep blood overnight. Several colonies 
were taken from these plates using sterile cotton swabs, suspended in sterile BHI 
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supplemented with yeast extract and casein. Each culture suspension was adjusted 
according to a 0.5 McFarland standard using a spectrophotometer 20. The suspensions 
were further diluted 1:100 in the same media. 
 ii.) Preparation of Antibiotic Solution. A stock solution of antibiotic was made by 
suspending 0.1g of antibiotic in 20 ml sterile distilled water resulting in 5mg/ml 
concentration. 2 ml of the stock was added to 98 ml of sterile BHI supplemented with 
yeast extract and casein. This corresponds to100 µg/ml antibiotic. 
 iii.) MIC Dilution Scheme. A series of 15 sterile 13 x 100 mm test tubes per 
antibiotic for each organisms to be tested was set up. Each tube contained 2 ml of sterile 
broth. Tube 1 and the negative control contained 50 µg/ml of antibiotic. Two-fold serial 
dilutions of antibiotic were prepared in the remaining tubes. 2 ml of the S. pneumoniae 
suspension was added to all tubes except the negative control. This halved the antibiotic 
concentrations in all tubes except the negative control. Tubes were incubated for 12 hrs at 
370C and 5% CO2.  
 iv.) Results interpretations. The MIC was determined by observing all tubes for 
visible growth. The MIC was defined as the lowest concentration of antibiotic at which 
the organism did not grow. Strains were categorized as susceptible, intermediate, or 
resistant to each antibiotic tested based on the standards set for S. pneumoniae (NCCLS). 
 
Bile Solubility Test 
 Strains were streaked onto Mueller-Hinton agar supplemented with 5% 
defibrinated sheep blood from frozen stocks. Cultures were incubated at 370C and 5% 
CO2 overnight (approximately 16 hrs). A cell suspension of the strains was made in BHI 
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broth supplemented with yeast extract and casein. The suspension was then standardized 
to approximately 40% T using a spectrophotometer. 400 µl of deoxycholate was added to 
4 ml of each suspension. The transmittance was then monitored using the 
spectrophotometer 20. Significant increase in transmittance was considered a positive test 
for bile solubility. A strain of Moraxella catarrhalis was used as a negative control. 
 
Optochin Test 
 The optochin test is a presumptive test that is used to identify strains of 
Streptococcus pneumoniae. Optochin is a surface active agent that specifically interacts 
with the cell membrane of S. pneumoniae to produce cell lysis. Optochin (ethyl 
hydrocupreine) disks are placed on inoculated blood agar plates. Because S. pneumoniae 
is not optochin resistant, a zone of inhibition will develop around the disk where the 
bacteria have been lysed. This zone is typically 14mm from the disk or greater. This test 
is usually performed on strains that may appear atypical or are not able to be serotyped 
 
Assay for β-lactamase Production by Cefinase Disk Test 
 The Cefinase disk test is a qualitative method to determine if organisms produce 
β-lactamases. The Cefinase disks were obtained from a commercial source (Difco, 
Bacton Dickinson). If the organisms produces a β-lactamase enzyme, the disk turns red as 
the chromogenic cephalosporin, nitrocefin is cleaved. If no color change occurs, then the 
organism does not produce a β-lactamase enzyme. A sterile Cefinase disk moistened with 
a drop of sterile water was placed into a sterile petri dish. From a S. pneumoniae culture 
grown overnight on a Mueller-Hinton blood agar plate, several well-isolated colonies 
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were removed using a sterile wire loop and smeared on the Cefinase disk. The disk was 
observed for a color change from its original yellow color to red. Moraxella catarrhalis 
was used as a positive control. A positive reaction suggests penicillin resistance by 
organisms that produce β-lactamases. 
 
Assay for Degradation of β-lactams by Sp D-2 
 An assay was used to determine whether the clinical isolate Sp-D2 that showed 
the highest level of resistance was in some way degrading the β-lactams as a mechanism 
of resistance. Sp-D2 was grown in the presence of 8 µg/ml of amoxicillin. (Sp-D2 MIC to 
amoxicillin is 31.25 µg/ml). After incubation overnight under standard conditions, the 
media was filtered to remove Sp-D2 cells. Serial dilutions of the filtered media were 
prepared with fresh media. Each tube was then inoculated with Sp Original whose MIC 
to amoxicillin is 0.12 µg/ml. If the antibiotic was degraded by Sp-D2, then Sp Original 
would be expected to grow in the dilution tubes that initially had high amoxicillin 
concentrations. As a positive control we used a strain of Moraxella catarrhalis obtained 
from Duke University that has been shown to produce β-Lactamases.  
 
Serotyping 
The Quelling reaction has been the "gold standard" method for typing of 
S. pneumoniae . The conventional method of serotyping S. pneumoniae uses 
pneumococcal typing antisera. The quellung reaction (swelling reaction) forms the basis 
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of serotyping and relies on the swelling of the capsule upon binding of anticapsular 
antibody (44) .  
 
SDS-PAGE of Whole-Cell Proteins of S. pneumoniae Strains 
Strains were analyzed using SDS-PAGE of whole-cell proteins. 
 i.) Preparation of Whole-Cell Lysates.  Each frozen strain was streaked on to 
Mueller-Hinton agar supplemented with 5% defibrinated sheep blood, then isolated 
colonies were Gram-stained to examine purity. Cells from plates were suspended in 50 
mM Tris buffer and adjusted to an optical density of 0.4 at 600 nM using a 
spectrophotometer 20. One ml of each culture suspension was transferred to a 
microcentrifuge tube and centrifuged for 1 minute at 4,400 x g. The supernatant was 
discarded via aspiration. The pellets were then resuspended in 30 ul of sample buffer and 
boiled for 10 minutes at 1000 C water bath. 
 ii.) Preparation of Gels. Polyacrylamide gels were prepared as described by 
Laemmli (41). The discontinuous vertical system composed of an upper stacking gel 
containing 6% polyacrylamide and a lower running gel containing 12.5 % 
polyacrylamide. The components of the running gel were first prepared and degassed for 
15 minutes. Then, TEMED was added, mixed and immediately poured into the vertical 
apparatus. The gel was allowed to polymerize for approximately one hour. The 
components of the stacking gel were then prepared, degassed for 15 minutes and after 
addition of TEMED, was poured slowly over the running gel.  The comb was inserted 
and allowed to polymerize for 30 minutes. 
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 iiii.) Electrophoresis. 10 µl of each sample was loaded into the designated wells. 
10 µl of the molecular weight standard (2 µl standard in 18 µl sample buffer) was also 
loaded into each gel. The gel was electrophoresed at 100 V for 30 min until the dye front 
reached the top of the running gel. The voltage was then reduced to 70 V and run for 
approximately 7 hours or until the dye front reached about 1 inch from the bottom of the 
gel. The gel was then stained in Coomassie blue for 15 minutes with shaking. The gel 
was then rinsed in distilled water and destained for 30 minutes. The gel was then left to 
further destain overnight in a pan of distilled water with a few drops of chloroform before 
photographing it. 
 
S. pneumoniae Cytoplasmic Membrane Isolation 
 Penicillin-binding proteins are located in the cytoplasmic membrane hence 
requiring a membrane extraction. S. pneumoniae strains were grown in 1 liter of BHI 
supplemented with yeast extract and casein up to the mid-logarithmic growth phase 
(approximately 7 hrs). Cells were harvested by centrifugation at 4,400 x g for 10 minutes. 
Pellets were then washed once in 50 mM potassium phosphate and 2 mM MgCL2 buffer 
and centrifuged for 20 min at 10,000 x g. Resulting cell pellets were resuspended in 
approximately 30 ml of the same buffer. 300 µl of 100 mM PMSF (phenylmethylsulfonyl 
fluoride) was added and mixed. 50 µg/ml DNase I  (Amoroso et el, 2001) was added and 
then the cells were passed through a French press 3 times at 1,000 kg/cm2. Unbroken 
cells were removed by centrifugation at 10,000 x g for 20 minutes twice. Another 300 µl 
of PMSF was added to the supernatant. The supernatants were then ultracentrifuged at 
110,000 x g for 2 hrs and 10 min at 150C (1, 95). The resulting membrane pellets were 
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solubilized in TritonX and stored  at –200C. The protein concentration of the membrane 
fraction was determined using the Bradford method. 
 
Detection of Penicillin-Binding Proteins with Bocillin 
 The procedure used for detection of S. pneumoniae penicillin-binding proteins 
was described by Zhao et al. BOCILLIN FL, a fluorescent penicillin was obtained 
commercially (Molecular Probes). The 1 mg content of BOCILLIN was dissolved in 1 ml 
of Methanol. Various concentrations of BOCILLIN were prepared by diluting in sterile 
distilled water. The S. pneumoniae frozen membrane fractions were thawed and various 
concentrations of these were prepared. 75 µl of each protein concentration was mixed 
with 25 µ of BOCILLIN and incubated in a 350C water bath for 30 minutes. The reaction 
mixture was then denatured with 100 µl SDS-denaturing solution at 1000C for 3 minutes. 
10 µl of each reaction was then subjected to SDS-PAGE. The polyacrylamide gel was 
prepared and run as described in the SDS-PAGE of whole cell section (see page 32). 
After running, the gel was rinsed off in distilled water and visualized under UV light 
(95). 
 
Generation of S. pneumoniae Step Mutants 
Gradient plates were prepared by pouring 20 ml of BHI supplemented with yeast 
extract and casein onto petri plates and letting them solidify at an angle to create a 
gradient to a point of zero. The plates were then leveled and 20 ml of BHI supplemented 
with yeast extract and casein containing 2 ug/ml ampicillin  (this concentration was the 
 44
initial concentration used but was increased with time) were poured into each plate and 
allowed to solidify. 
Strains were removed from the freezer and streaked onto Mueller-Hinton agar 
supplemented with 5% defibrinated sheep blood. The plates were incubated at 370C in a 
candle jar overnight (15-16 hrs). From each plate, isolated colonies were used to make a 
suspension in sterile saline. 0.2 ml of each strain was spread onto the 2ug/ml gradient 
plates using the spread plate method. The plates were then inverted and grown under the 
same conditions for 24 hrs. Isolated colonies growing at the highest concentration of 
ampicillin were streaked on the same plate towards the higher concentration areas of the 
plates. The plates were re-incubated under the same conditions. The colonies were then 
picked and transferred to another fresh plate containing 2 ug/ml ampicillin. The above 
procedure was then repeated with plates containing higher concentrations of ampicillin. 
Strains were frozen periodically when they attained certain levels of ampicillin (2 ug/ml, 
3 ug/ml, 5 ug/ml, 7 ug/ml). The concentrations at which the mutants grew were verified 
by plating on fresh media containing various ampicillin concentrations.  
 
DNA Isolation of S. pneumoniae Strains 
 The method used for isolation of S. pneumoniae DNA is a modified procedure by 
Whatmore et al. S. pneumoniae strains were grown in 500 ml of BHI supplemented with 
yeast extract and casein at 370C and 5% CO2 overnight (approximately 16 hrs). Cells 
were harvested by centrifugation at 4,400 x g for 10 minutes. Cell pellets were 
resuspended in 5 ml of a solution containing 50 mM Tris-HCL and 10 mM EDTA 
adjusted to pH 8.0. 25 µl of 20 mg/ml lysozyme was added and the suspension was 
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incubated in a 370C water bath for 10 min. 25 µl of 10 mg/ml proteinase K was added and 
incubated for another 30 min. After incubation, 200 µl of 20% Sarkosyl was added and 
mixed. The final suspension was then subjected to a phenol extraction and a chloroform 
extraction. The DNA was then precipitated in 95% cold ethanol with 10% 3 M sodium 
acetate (pH 5.2). DNA was spooled using a glass rod and placed in clean vials  (89). The 
DNA was resuspended in 1-2 ml of sterile distilled water with a few drops of chloroform 
and stored at room temperature. DNA concentration was determined using a UV 
Spectrophotometer. 
 
Trypsin In-Gel Digest 
In order to study the unique protein band exhibited by strain Sp D2, it was 
necessary to extract proteins bands from the SDS-PAGE gels. The ProteoProfileTM 
Trypsin In-Gel Digest kit was used for the purpose (Sigma). Protein bands from 1D SDS-
PAGE gels were processed according to the manufacture procedure. The bands of interest 
were excised using a clean scalpel and placed in siliconized eppendorf tubes, one gel 
piece per tube. Each gel piece was covered with 200 µl of destaining solution (containing 
200 mM ammonium bicarbonate and 40% acetonitrile) and incubated at 370 C for 30 
minutes. The solution was then discarded and the step repeated one more time. The gel 
pieces were dried on Kim Wipes. 20 µl of the prepared trypsin solution was then added 
followed by 50 µl of the trypsin reaction buffer. The gel pieces were incubated for 8 
hours at 370 C in a sonic bath (Fisher Scientific, Bransonic). After incubation, the liquid 
from the gel was transferred to new siliconized eppendorf tubes. 50 µl of the peptide 
extraction solution was added to the gel pieces and re-incubated for 30 minutes. The 
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peptide extraction solution was then removed and combined with the liquid from the first 
incubation (5, 93, 94). 
 
Preparation of Peptide Samples for Mass Spectrometry Analysis 
Peptide samples were purified and concentrated by use of a Zip Tip (Millipore) 
which has C18 resin fixed at its end and rinsed according to the manufacture’s instructions 
in 10 µl of 0.1% trifluoroacetic acid (TFA) and 50% acetonitrile (ACN). Peptides were 
eluted in 10 µl 1:1 ACN-0.1 % TFA. A 0.5 µl volume of the concentrated peptide-
containing sample was mixed with 0.5 µl of a saturated solution of α-cyano-4-
hydroxycinnamic acid. 0.5 µl of each sample was spotted on the mass spectrometer 
sample plate (84, 93, 94). 
 
Protein Identification by MALDI-TOF MS 
Mass spectra were obtained on a matrix assisted laser desorption and ionization / 
time-of-flight mass spectrometer (MALDI-TOF), TOF/TOFTM 4700 Proteomics analyzer 
(Applied Biosystems) at two different core labs, Georgia Institute of Technology and 
Emory Univeristy core labs.  
MALDI spectra were calibrated using a peptide mixture provided by the 
manufacturer (Applied Biosystems). Protein identifications were realized by the method 





Database Searches for Protein Identification 
Monoisotopic peptide masses obtained from mass spectra were searched against 
the SWISS-PROT, NCBInr and MSDB databases using the MASCOT search program. 
The following parameters were used in the searches: Bacteria (Eubacteria) or S. 
pneumoniae, MS/MS Ion Search, protein mass of 50 kDa, trypsin digest with two missed 
cleavages, fragment ion mass tolerance of ± 75 ppm and possible oxidation of methionine 
(84). 
N-terminal Sequencing 
Sp D2 protein samples were further analyzed by the Emory core facility. Sp D2 
protein samples were subjected to SDS-PAGE/blotting onto PVDF membrane and 
stained with Amido Black yielding a profile. The major band of interest was excised and 
sequenced using 18 Edman degradation cycles yielding an N-terminal sequence.  WU-
BLAST was used to search the Swall database with the N-terminal sequence data 
 
Genetic Analysis of Clinical Isolates for Genes that Encode for Virulence Factors 
Pneumolysin gene (ply) 
 In order to further characterize our clinical isolates and to positively identify them 
as S. pneumoniae strains, PCR was performed on the strains targeting genes encoding 
three major virulence factors; pneumolysin, autolysin and pneumococcal surface antigen. 
 For pneumolysin, two primers and one probe were selected based on published 
pneumolysin gene sequence (70). A nested PCR approach was taken. The outer primers 
(5’-ATTTCTGTAACAGCTACCAACGA-3’) and (5’-
AATTCCCTGTCTTTTCAAAGTC-3’), amplified a 348-bp region of the pneumolysin 
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gene. The inner primers (5’-CCCACTTCTTCTTGCGGTTGA-3’) and (5’-
TGAGCCGTTATTTTTTCATACTG-3’), amplified a 208-bp region (10, 18, 69, 70).  
 Amplification was carried out in an automated thermal cycler (Perkin-Elmer). The 
50 µL reaction mixture contained 50 mM KCL, 10 mM Tris-Hcl pH 8.3, 1.5mM MgCl2, 
0.01% (vol/vol) gelatin, 5 mM deoxyribonucleotides, 50 pmol primers, 2.5 units of Tag 
DNA polymerase (Promega), and various amounts of DNA extracted from the strains. 
Amplification was done using 30 cycles of denaturation at 940C for 1 min, followed by 
annealing of the primers at 550C for 1 min and synthesis at 720C for 1 min. Nested 
amplifications were done in the same manner. Negative control was distilled water and 
positive control was previously tested pneumococcal DNA. A 10µL volume of the 
completed reaction mixture was run in a 1.5% agarose gel stained in ethidium bromide 
(22, 38, 39, 47, 56, 69, 70, 80, 86, 87).  
 
Autolysin gene (lytA)  
 A nested PCR approach was undertaken in the same manner as described for the 
ply amplification. The outer primers used were (5’-GGCTACTGGTACGTACATTC-3’)  
and (5’-AATCAAGCCATCTGGCTCTA-3’). The inner primers used were (5’-
ATCCAAAAGACAAGTTTGAGA-3’) and (5’-CTGGATAAAGGCATTTGATAC-3’). 
PCR reaction was carried out in the same manner as described above (55). 
 
Pneumococcal surface antigen gene (psaA)  
 Single primers were used to amplify the psA gene. The forward primer was (5’-
CTTTCTCTGCAATCATTCTTG-3’) and the reverse primer was (5’-
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GCCTTCTTTACCTTGTTCTGC-5’). The PCR reaction was otherwise carried out in 
much the same manner as described above (60). 
 
Discrimination of S. pneumoniae by Arbitrarily Primed PCR 
 In clinical laboratories, identification of S. pneumoniae from other streptococci is 
important especially in cases where strains are not able to be serotyped. If a strain cannot 
be serotyped, an arbitrarily primed PCR with a single primer M13 universal is used as a 
method to distinguish S. pneumoniae from other upper respiratory tract streptococci (54). 




















Kirby-Bauer Susceptibility Tests 
The Kirby-Bauer method is a qualitative test to determine if bacteria are 
susceptible or resistant to an antimicrobial agent. Four antimicrobial agents were tested 
including three β-lactams (ampicillin, ceftazidime and amoxicillin) and a glycopeptide 
(vancomycin). All clinical isolates from Duke University and Grady hospital were 
resistant to ampicillin (Table 4). The Duke strains exhibited extremely high resistance 
with no zones of inhibition. The resistance break point of S. pneumoniae to ampicillin 
using the Kirby-Bauer method, is any value less than 21 mm diameter of inhibition zone. 
The vaccine strains and Sp Original, a clinical isolate from Boston hospital showed 
intermediate susceptible to ampicillin. Only one organism, Sp D2 was resistant to 











TABLE 4:  Kirby-Bauer Susceptibility Results for S. pneumoniae 
 
aStrain Ampicillin Ceftazidime Vancomycin Amoxicillin 
 10 mcg 30 mcg 30 mcg 30 mcg 
Sp D-1 14 (res) 20 (sus) 20 (sus) 27 (sus) 
Sp D-2 0 (res) 10 (res) 25 (sus) 12 (res) 
Sp D-3 0 (res) 21 (sus) 25 (sus) 30 (sus) 
Sp D-4 0 (res) 20 (sus) 22 (sus) 30 (sus) 
Sp D-5 0 (res) 16 (int) 22 (sus) 20 (sus) 
Sp D-6 0 (res) 21 (sus) 24 (sus) 32 (sus) 
Sp G-25053 15 (res) 22 (sus) 24 (sus) 34 (sus) 
Sp G-31159 13 (res) 25 (sus) 21 (sus) 31 (sus) 
Sp G-5481 12 (res) 22 (sus) 22 (sus) 30 (sus) 
Sp G-31483a 14 (res) 21 (sus) 23 (sus) 34 (sus) 
Sp Original 29 (int) 34 (sus) 24 (sus) 48 (sus) 
Sp 83 24 (int) 32 (sus) 24 (sus) 43 (sus) 
Sp 86 26 (int) 32 (sus) 24 (sus) 40 (sus) 
Sp 95 25 (int) 31 (sus) 24 (sus) 38 (sus) 
Sp 105 25 (int) 32 (sus) 23 (sus) 38 (sus) 
Sp 117 28 (int) 34 (sus) 25 (sus) 42 (sus) 
Sp 125 25 (int) 32 (sus) 24 (sus) 40 (sus) 
bBreak point of < 21 mm < 14 mm < 9 mm < 13 mm 
resistance  
 
a Abbreviation for source of strains: Sp D = Duke strains, Sp G = Grady strains 






Minimal Inhibitory Concentration (MIC) Test 
The minimum inhibitory concentration test (MIC) is a quantitative susceptibility 
test. In these experiments, a broth macro dilution method was used determine the 
minimal concentration of antibiotics that will inhibit growth of representative strains. 
Three antibiotics were tested, penicillin G, ampicillin and amoxicillin all of which are 
routinely used to treat S. pneumoniae infections (Severina et al, 1999). According to the 
NCCLS guidelines, S. pneumoniae is considered resistant if its MIC to penicillin G is > 2 
µg/ml, to ampicillin is > 4 µg/ml, and to amoxicillin is > 2 µg/ml. Two strains from Duke 
University, Sp D1 and Sp D2 were found to be resistant: Sp D1 had a MIC of 6.25 µg/ml 
for ampicillin and SP D2 had a MIC of  4.0 µg/ml for penicillin G, > 25 µg/ml for 
ampicillin, and 31.25 µg/ml for amoxicillin (Table 6). One Vaccine strain (Sp 117) was 
resistant to penicillin G with a MIC of 3.125 µg/ml. Sp Original was susceptible to all 
three β-lactams tested here. The Grady strains showed varied results: Sp G-25053 was 
resistant to ampicillin, but intermediate for penicillin G; Sp G31159 and Sp G-5481 were 
susceptible to both β-lactams tested; and Sp G-31483a was resistant to both penicillin G 















TABLE 5:  Minimal Inhibitory Concentration (MIC) Results for S. pneumoniae 
 
 
aStrain Penicillin G Ampicillin Amoxicillin 
 MIC ug/ml MIC ug/ml MIC ug/ml 
Sp D-1 6.25 (res) not done not done 
Sp D-2 4 (res) > 25 (res) 31.25 (res) 
Sp G-25053 1.56 (int) 9.38 (res) not done 
Sp G-31159 0.048 (sus) 0.39 (sus) not done 
Sp G-5481 0.39 (sus) 0.78 (sus) not done 
Sp G-31483a 6.25 (res) 25 (res) not done 
Sp Original 0.015 (sus) 0.195 (sus) 0.12 
Sp 83 0.003 (sus) 0.195 (sus) not done 
Sp 86 0.005 (sus) 0.098 (sus) not done 
Sp 95 0.006 (sus) 0.195 (sus) not done 
Sp 105 0.048 (sus) 0.098 (sus) not done 
Sp 117 3.125 (res) 0.098 (sus) not done 
Sp 125 0.098 (sus) not done not done 
bBreak point of > 2 ug/ml > 4 ug/ml > 2 ug/ml 
resistance 
 
a Abbreviation for source of strains: Sp D = Duke strains, Sp G = Grady strains 
bThe interpretive standards: Res = resistant, Sus = susceptible, Int = intermediate 
 
 
Assay for β-Lactamase Production by Cefinase Disk Test 
 The Cefinase test was performed on all strains. The Cefinase test determines if 
organisms produce a lactamase enzyme. The Cefinase disk is similar to an antibiotic disk 
and is impregnated with a chromogenic cephalosporin. This cephalosporin, called 
nitrofecin, turns red as the amide bond in the β-lactam ring of the nitrocefin is hydrolyzed 
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by a β-lactamase enzyme. To date, no S. pneumoniae strain has been demonstrated to be 
β-lactamase positive but over 90% of Moraxella catarrhalis strains worldwide are β-
lactamase positive (9). In this study none of the S. pneumoniae strains were β-lactamase 
positive. 
  
SDS-PAGE of Whole-Cell Proteins of S. pneumoniae Strains 
 A profile of whole-cell proteins from 17 S. pneumoniae strains as determined by 
SDS-PAGE is shown in Figures 3 and 4. Some strains from Figure 3 were repeated in 
Figure 4 in an effort to obtain better resolved bands. The profile shows some differences 
and similarities between the test organisms. All of the organisms exhibit several common 
major bands and a few distinct differences. There are some high-molecular-weight bands 
that are not exhibited in all of the test strains. For example, test organism Sp D2 exhibited 
a band at approximately 50 kDa that is not present in any other test strain. The protein 
band exhibited by Sp D2 at approximately 50 kDa was most unique and highly resolved 
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Figure 3:  SDS-PAGE of S. pneumoniae Whole-Cell Proteins. Lane 1, Low MW marker 
(97.4, 66.2, 45.0, 31.0, 21.5 kDa); Lane 2, D-1; Lane 3, D-2.; Lane 4, D-3; Lane 5, D-4; 
Lane 6, D-5;  Lane 7, D-6;  Lane 8, G-25053;  Lane 9, G-31159;  Lane 10, G-31483a; 
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Figure 4:  SDS-PAGE of S. pneumoniae Whole-Cell Proteins (Continued) . 
Lane 1, Low MW marker; Lane 2, Sp Original; Lane 3, Sp 83; Lane 4, Sp 86; Lane 5, Sp 
95; Lane 6, Sp 105; Lane 7, empty; Lane 8, Sp 117; Lane 9, Sp 125; Lane 10, G-25053; 
Lane 11, G-31483a; Lane 12, G-5481; Lane 13, High MW marker (200, 116.25, 97.4, 









Detection of S. pneumoniae Penicillin-Binding Proteins (PBPs) 
BOCILLIN FL is a commercially available fluorescent penicillin that can be used 
as a labeling reagent for penicillin-binding proteins (95). In order to determine the 
optimum range of BOCILLIN FL and membrane protein concentrations required for 
detection, it was necessary to optimize the system. Serial dilutions of membrane fractions 
from Sp G-25053 and Sp 95 were made, each of which was labeled with different 
concentrations of BOCILLIN FL (50 µM and 25 µM . The labeled membrane 
preparations were separated by SDS-PAGE and detected under UV light (Figure 5). 
There were two distinct bands (molecular weight not determined). The slower migrating 
band is faint, and it was later determined that BOCILLIN FL is unstable under UV light 
thus requiring rapid photography. Results showed that the concentration of BOCILLIN 
FL used was more significant than the protein concentrations. Fractions labeled with 25 
µM BOCILLIN FL (lanes 7 -12) showed less fluorescence than those labeled with 50 µM 
BOCILLIN FL (all other lanes). There was no obvious difference in fluorescence 
intensities with the varied protein concentrations. 
Due to the rapid loss of fluorescence intensities, this method did not prove to be 








                                                           





Figure 5:  Detection of PBPs of S. pneumoniae. Lane 1, Low MW marker (not visible 
under UV light); Lane 2, 225 µg/ml protein of Sp G25053 and 50 µM Bocillin ; Lane 3, 
112.5 µg/ml protein of Sp G25053 and 50 µM Bocillin ; Lane 4, 56.25 µg/ml protein of 
Sp G25053 and 50 µM Bocillin; Lane 5, 22.12 µg/ml protein of Sp G25053 and 50 µM 
Bocillin; Lane 6, 14 µg/ml protein of Sp G25053 and 50 µM Bocillin; Lane 7, 225 µg/ml 
protein of Sp G25053 and 25 µM Bocillin; Lane 8, 112.5 µg/ml protein of Sp G25053 
and 25 µM Bocillin; Lane 9, 56.25µg/ml protein of Sp G25053 and 25 µM Bocillin; Lane 
10, 28.12µg/ml protein of Sp G25053 and 25 µM Bocillin; Lane 11, 14µg/ml protein of 
Sp G25053 and 25 µM Bocillin; Lane 12, 27.5 µg/ml protein of Sp 95 and 50 µM 
Bocillin; Lane 13, 18.75 µg/ml protein of Sp 95 and 50 µM Bocillin; Lane 14, 9.37 µg/ml 
protein of Sp 95 and 50 µM Bocillin; Lane 15, 4.68 µg/ml protein of Sp 95 and 50 µM 





Generation of S. pneumoniae Step Mutants 
 Two representative strains Sp G31159 and Sp Original were used to generate step 
mutants by the gradient plate technique. Ampicillin is routinely used to treat S. 
pneumoniae infections and therefore this β-lactam was chosen to generate the mutants. 
The first gradient plates contained a maximum ampicillin concentration of 2 µg/ml. Sp 
Original was stepped up to 5 µg/ml and Sp G31159 was stepped up to approximately 7 
µg/ml. These values have been verified by plating on fresh ampicillin plates containing 5 
µg/ml and 7 µg/ml respectively. The step mutants were periodically stored in Mueller 
Hinton broth and glycerol at -200 C and -700 C while performing these experiments. 
 
Sp D2 Unknown Protein Analysis 
Whole cell SDS-PAGE results shown in Figure 3, lane 3, revealed a protein 
unique to Sp D2 that is approximately 50 kDa. Due to the high level of resistance of this 
particular strain, this unique protein was of interest. In an attempt to characterize this 
protein, several procedures were performed. Firstly, Since PBPs are membrane bound 
enzymes, the membrane proteins of several of the strains were isolated including Sp D2 
in attempt to determine if the unique protein is membrane bound. The membrane 
fractions were run on an SDS-PAGE gel (Figure 6). Results indicate that the unique 
protein of approximately 50 kDa is present in the Sp D2 membrane fraction (Lanes 2 to 
5) shown in Figure 6. Sp Original was used as a control and the unique protein is not 
present in the Sp Original membrane fraction lanes, and was not present in whole-cell 




   



















Figure 6: SDS-PAGE of S. pneumoniae membrane fractions. Lane 1, Low MW marker; 
Lanes 2 - 5, Sp D-2; Lane 6, empty, Lane 7, Sp Original; Lane 8 High MW marker (200, 
116.25, 97.4, 66.2, 45 kDa). Sp D2 membrane fractions were run on replicated (lanes 2-










Sp D2 Growth Curve with Whole Cell SDS-PAGE Analysis  
 A growth curve study was also performed on Sp D2 (Figure 7). Cells were 
sampled periodically and analyzed on SDS-PAGE to determine whether the Sp D2 
protein of interest was present throughout the growth period (Figure 8). Based on these 
results, there was evidence of two protein bands. The bottom band appeared to increase in 
intensity with time but the top band maintained the same intensity throughout the 

























































Figure 8: SDS-PAGE of Sp D2 whole cell proteins from growth curve sampling. Lane 1, 



















MALDI-MS Analysis of Sp D2 Protein Band 
The distinct Sp D2 protein band of approximately 50 kDa was excised from the 
membrane fraction SDS-PAGE gel (See Lanes 2-5, Figure 6) and processed using a 
trypsin In-Gel digest kit. Trypsin cleaves after Lysine and Arginine residues (except if 
they are before Proline) therefore producing specific fingerprints for specific proteins. 
Resulting peptide digests were then analyzed by MALDI-MS (matrix-assisted 
laser desorption and ionization mass spectrometry). Figure 9 represents the MALDI-MS 
data of the digests. The tallest five peaks were selected by an automated procedure and 
analyzed further by MALDI-MS/MS also referred to as tandem mass spectrometry 
(Figures 10-14).  
Figure 10, represents the 3358 Da peptide, Figure 11, represents the 2894 Da 
peptide, Figure 12, represents the 2878 Da peptide, Figure 13, represents the 2244 Da 


















































































































Figure 14: MALDI-MS/MS spectra of Sp D2 2102 Da peptide
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Database Searches for Sequence Similarity With Sp D2 MS Results 
The In-gel digests obtained from the band of interest were analyzed by MALDI-
MS yielding a peptide mass fingerprint. The monoisotopic peptide masses obtained were 
searched against the SWISS-PROT, NCBInr and MSDB databases using the MASCOT 
search program. The resulting protein hits are scored using a probability based Mowse 
score. The score is -10*Log (P), where P is the probability that the observed match is a 
random event.  
The results from the database searches sowed only one protein CagA (from 
Helicobacter pylori) received a marginal significant score from the NCBInr and MSDB 
databases but not from the Swissprot database. As a result, this is not considered a true 
protein match. No protein was identified as having a significant score when searched 
against S. pneumoniae data available in all three databases. The proteins listed as the top 
scoring proteins from all databases do not share any apparent similarities. The MALDI-
MS and MS/MS results therefore did not provide a conclusive identification of the Sp D2 
unknown protein.  
 
N-terminal Sequence Data 
Sp D2 protein samples were subjected to SDS-PAGE/blotting onto PVDF 
membrane and stained with Amido Black yielding a profile. The major band of interest 
was excised and sequenced using 18 Edman degradation cycles yielding an N-terminal 
sequence.  WU-BLAST was used to search the Swall database with the N-terminal 
sequence data. There were no significant matches obtained from the database which 
included S. pneumoniae proteome. The only similarity shared by the proteins is that they 
 71
appear to be membrane bound. The N-terminal sequence obtained is as follows: 
DSSFDKLVADALGITAPA (18 amino acids) 
  
Internal Sequence Data 
 A Trypsin In-gel digest was performed on the band of interest. The digest was 
fractionated by HPLC and purified peptides were subjected to 23 cycles of Edman 
degradation in order to determine internal sequences. The resulting sequence were 
analyzed in the same manner as the N-terminal sequence. Like the N-terminal sequence 
data, there were no significant matches and none from S. pneumoniae proteome. The 
internal sequences obtained are as follows:  
VLNDAIEALTNAIANGTGSVDGK  (23 amino acids), DKIDADFAGDLS  (12 
amino acids) and KAYSDAVYAVR  (11 amino acids). 
 
Serotype Studies and Additional Biochemical Characterization of S. pneumoniae Clinical 
Isolates 
Serotyping is the golden standard of discriminating between S. pneumoniae 
strains based on their capsular type and is the basis of the current capsular polysaccharide 
vaccines. Serotyping of the clinical isolates was conducted using antisera to 
polysaccharide capsules representing all documented capsular types. Results showed that 
isolates in my study represented a wide variety of serotypes (Table 6). Three strains, Sp 
D-2, Sp Original and Sp G-5481 were non-typeable, which means that they could not be 
identified as having any of the documented capsular types. The most common serotype 
expressed is 14, exhibited by six strains.  
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The Optochin test and bile solubility tests are routinely used as biochemical tests 
for presumptive identification of S. pneumoniae. All strains except Sp G-5481 tested 
positive by the bile solubility and optochin test, this strain is also non-typeable. Sp 
Original showed variable results for the optochin test (Table 14).  
  
TABLE 6:  Results for Serotype Studies, Bile Solubility and Optochin Test  
 
aStrain Gram stain Serotype Bile solubility Optochin test
Sp D-1 gram + 9V + + 
Sp D-2 gram + bnon-typeable + + 
Sp D-3 gram + 6A + + 
Sp D-4 gram + 19F + + 
Sp D-5 gram + 14 + + 
Sp D-6 gram + 6B + + 
Sp D-7 gram + 19F + + 
Sp D-8 gram + 14 + + 
Sp D-9 gram + 14 + + 
Sp D-10 gram + 14 + + 
Sp D-11 gram + 14 + + 
Sp D-12 gram + 14 + + 
Sp G-25053 gram + 9V + + 
Sp G31159 gram + 18C + + 
Sp G-5481 gram + bnon-typeable - - 
Sp G-3143a gram + 23F + + 
Sp Original gram + bnon-typeable + +/- 
 
aAbbreviation for source strains Sp D = Duke strains, Sp G = Grady strains 
bNon-typeable = strains that cannot be serotyped and fit the standard definition of non-
typeable  S. pneumoniae based on the other test results in the above table 
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Additional Antibiotic Susceptibility Testing of Sp D2 
 




Interpretation Antibiotic Classification 
 
Penicillin 4 R β-lactam 
Chloramphenicol 4 S Chloramphenicol 
Tetracycline* 0.25 S Tetracycline 
Erythromycin* >2 R Macrolide 
Clindamycin* 0.06 S Macrolide 
Trimethoprim/Sulfamethoxazole* 8/152 R Sulfonamide/antimetabolite
Cefotaxime (nonmeningitis)* 8 R Cephalosporin/β-lactam 
Cefotaxime (meningitis) 8 R Cephalosporin/β-lactam 
Ceftriaxone (nonmeningitis)* 4 R Cephalosporin/β-lactam 
Ceftriaxone (meningitis) 4 R Cephalosporin/β-lactam 
Cefepime (nonmeningitis)* 2 I Cephalosporin/β-lactam 
Cefuroxime >4 R Cephalosporin/β-lactam 
Meropenem 1 R Carbapenem/β-lactam 
Imipenem* 0.5 I Carbapenem/β-lactam 
Levofloxacin* 1 S Fuloroquinolone 
Vancomycin 0.5 S Glycopeptide 
 
*Not appropriate for treatment of meningitis 
 
Additional antibiotic susceptibility tests were performed on Sp D2, using 
antibiotics not studied in my initial thesis results. Sp D2 was found to be resistant to a 
majority of the antibiotics (Table 7). It exhibited resistance or intermediate resistance to 
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all cephalosporins and carbapenems tested. As mentioned earlier, cephalosporins and 
carbapenems are β-lactams like penicillin in that they all inhibit cell wall synthesis. Sp 
D2 is susceptible to four antibiotics, chloramphenical, tetracycline, clindamycin (a 
macrolide), levofloxacin and vancomycin. However, tetracycline, clindamycin and 
levofloxacin are not suitable for treatment of meningitis.  
 
PCR of Pneumococcal Surface Antigen, Autolysin and Pneumolysin Genes 
 In order to further characterize Sp D2 and positively identify it as a S. 
pneumoniae, several PCR procedures were used to determine the presence of common S. 
pneumoniae virulence factors. The genes targeted were the pneumococcal surface protein 
(psaA) gene, autolysin (lytA), and pneumolysin (ply) genes (Table 8). These PCR studies 
were also performed on the other clinical isolates. 
 All strains were positive for the presence of pneumococcal surface antigen (psaA) 
gene. All strains also showed the presence of autolysin (LytA) gene. Two strains, Sp-D6 
and Sp D-11 did not show an amplification of the pneumolysin (Ply) gene using outer 
primers but were positive with the inner primers. Two of the Grady strains Sp G-31159 
and G-5481 did not appear to have the Pneumolysin gene based on the use of two sets of 
primers. 

















Sp D-1 + + + + 
Sp D-2 + + + + 
Sp D-3 + + + + 
Sp D-4 + + + + 
Sp D-5 + + + + 
Sp D-6 + + - + 
Sp D-7 + + + + 
Sp D-8 + + + + 
Sp D-9 + + + + 
Sp D-10 + + + + 
Sp D-11 + + - + 
Sp D-12 + + + + 
Sp G-25053 + + + + 
Sp G31159 + + - - 
Sp G-5481 + + - - 
Sp G-3143a + + + + 
Sp Original + + + + 
 
aAbbreviation for source strains Sp D = Duke strains, Sp G = Grady strains 
bouter = outer primers used in the nested PCR 




Correlation Studies Between Serotypes and PCR of  S. pneumoniae Virulence 
Genes 
There was no particular correlation between any specific serotype and the PCR 
results (Table 9). The pneumococcal surface protein (PsaA) gene appears to be present in 
all serotypes. This correlates with observation from other studies discussed earlier. All 
serotypes also showed the presence of autolysin (lytA) gene. The pneumolysin gene (ply) 
could not be amplified using nested PCR outer primers in two isolates with serotype 6B 
(Sp D-6) and serotype 14 (Sp D-11), but could be amplified using inner primers. Two 
isolates Sp G-31159 (serotype 18 C) and Sp G-5481 (non-typeable) did not appear to 
have the pneumolysin gene. 
 
 
Correlation Studies Between Serotypes and Occurrence in Drug Resistance, 
Pediatric and Adult Infections. 
Table 10 represents correlation studies between serotypes and their common 
occurrence associated with drug resistance, pediatric infections and adult infections. 
Other studies have shown that the most important pediatric serotypes are 6A, 14, 19F and 
23Fs. In adults however, serotypes 3, 19F and 6A accounted for only 31% of the isolates 
(2). The serotypes 6B, 9V, 14, 19A, 19F, and 23F cause most drug-resistant infections in 
the United States (36).  
My results indicate that most of the clinical isolates have serotypes associated 
with drug resistance, and three of the ones not grouped are non-typeable. These results 
correlate with the susceptibility profiles presented above, majority of the clinical isolates 
were resistant to at least one antibiotic. Majority of the isolates also have serotypes 
frequently associates with pediatric infections which is expected since they were isolates 
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from Otitis Media cases. Only three isolates (Sp D3, Sp D4, and Sp D7) have serotypes 
associated with adult infections.  
 
 
TABLE 9: Correlation Between Serotypes and PCR of Virulence Genes 
 












Sp D-1 9V + + + + 
Sp D-2 bnon-typeable + + + + 
Sp D-3 6A + + + + 
Sp D-4 19F + + + + 
Sp D-5 14 + + + + 
Sp D-6 6B + + - + 
Sp D-7 19F + + + + 
Sp D-8 14 + + + + 
Sp D-9 14 + + + + 
Sp D-10 14 + + + + 
Sp D-11 14 + + - + 
Sp D-12 14 + + + + 
G-25053 9V + + + + 
G-31159 18C + + - - 
G-5481 bnon-typeable + + - - 
G-3143a 23F + + + + 
Original bnon-typeable + + + + 
 
aAbbreviation for source strains Sp D = Duke strains, Sp G = Grady strains 
bouter = outer primers used in the nested PCR 
cinner = inner primers used in the nested PCR 
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TABLE 10: Correlation Between Serotypes and Occurrence in Drug Resistance, 
Pediatric and Adult Infections. 
 









Sp D-1 9V +   
Sp D-2 bnon-typeable    
Sp D-3 6A  + + 
Sp D-4 19F + + + 
Sp D-5 14 + +  
Sp D-6 6B +   
Sp D-7 19F + + + 
Sp D-8 14 + +  
Sp D-9 14 + +  
Sp D-10 14 + +  
Sp D-11 14 + +  
Sp D-12 14 + +  
Sp G-25053 9V +   
Sp G31159 18C    
Sp G-5481 bnon-typeable    
Sp G-3143a 23F + +  
Sp Original bnon-typeable    
 
aAbbreviation for source strains Sp D = Duke strains, Sp G = Grady strains 
bNon-typeable = strains that cannot be serotyped and fit the standard definition of non-










Assay for Degradation of β-Lactams by Sp D-2 
 Since Sp-D2 exhibited the highest level of resistance to β-Lactam antibiotics and 
due to the presence of the unique protein, we used an assay to determine if Sp-D2 was 
possibly degrading β-Lactams. Production of β-Lactamases is the common mechanism 
of breaking down β-Lactams by certain organisms such as Moraxellae catarrhalis. In 
order to treat infections caused by β-Lactamase producing strains, antibiotics combined 
with β-Lactamase inhibitors such as clavulanate acid are administered. The most 
common treatment being amoxicillin-clavulanate acid, otherwise known as augmentin.  
For the assay we chose amoxicillin without the inhibitor. Results of our study showed 
that when Sp-D2 is grown in the presence of amoxicillin levels below the MIC, the 
organism grows. This growth media was filtered to remove the Sp D2 cells and further 
diluted to be used to culture Sp Original. The amoxicillin concentration remained the 
same and Sp Original growth was inhibited. When the same assay was repeated with the 
presence of a Moraxellae catarrhalis strain that has been shown to produce β-
Lactamase, Sp Original grew in all tubes. This indicates that Sp-D2 did not break down 









CHAPTER V  
 
DISCUSSION AND CONCLUSIONS 
 
Antibiotic Susceptibilities and SDS-PAGE Analysis 
 The first phase of my research focused on S. pneumoniae and its increased level 
of resistance to β-lactam antibiotics. This increase in resistance has been attributed 
mostly to horizontal gene transfer since this species is a naturally transformable 
organism.  
 All strains in this study were characterized using SDS-PAGE. This is an 
important molecular epidemiological tool because it generates a profile that can 
distinguish between strains that otherwise may have very similar characteristics based on 
phenotypic and biochemical tests (75). The SDS-PAGE profiles yielded some major 
bands of proteins present in all strains. However, unique bands were found in certain 
strains that may be used to distinguish one strain from the others. Sp D2 especially 
exhibited a unique highly concentrated band with a molecular weight of approximately 
50 kDa. 
 Another aspect of the research was to determine the susceptibility patterns of 
these organisms from different sources and geographical regions. Bacterial pathogens 
have become increasingly resistant to commonly used antibiotics. This increased 
resistance to antimicrobial agents is occurring in many countries and has complicated 
medical and economic health care decision-making. Some of these microorganisms are 
not easily treated with narrow spectrum antibiotics resulting in the use of broader and 
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usually more expensive agents (46). It has thus become necessary to stay up-to-date on 
bacterial antibiotic resistance patterns because these change over time. It is therefore 
recommended that there should be routine susceptibility testing of organisms and their 
mechanisms of resistance studied (46). This allows the best balance in avoiding 
unnecessary use of broad-spectrum antibiotic therapy while aggressively treating resistant 
pathogens (46). 
The β-lactams are by far the most widely used and efficacious of all antibiotics. 
The current choice of treatment for pneumococcal infections are β-lactams, most of 
which are penicillin derivatives. The evolution of frequent, high-level penicillin 
resistance in the pneumococcus has led to a reappraisal of the treatment of common 
respiratory tract infections. This includes a return to routine susceptibility testing of 
pneumococcal clinical isolates, looking for penicillin resistance in pneumococci and re-
examination of the utility of pneumococcal vaccine in prevention of clinical infections 
(46).  
Antibiotic susceptibility test results of this study correlate with this phenomena of 
increased high level resistance by S. pneumoniae. There were eleven clinical isolates used 
in this study plus the six strains used in the formulations of one widely used 
pneumococcal vaccine. Ten out of the eleven clinical isolates showed resistance to 
Ampicillin, with five of them being extremely high, such that there were no zones of 
inhibition in the Kirby Bauer test. Only one isolate (Sp D2) showed resistance to all the 
β-lactam antibiotics used. All strains were however still susceptible to Vancomycin, the 
only none β-lactam antibiotic used in my study.  
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All strains were negative for the production of a β-lactamase enzyme using the 
Cefinase disk test. These results correlate with the known observation that to this date, no 
β-lactamase producing S. pneumoniae strain has been described (9). On the other hand, 
over 90% of Moraxella catarrhalis strains worldwide are β-lactamase positive (9). This is 
an interesting observation since both organisms co-exist in the upper respiratory tract. 
With S. pneumoniae being a natural transformant, it is feasible that they would pick up 
some β-lactamase encoding genes from these organisms existing in such close proximity. 
This has however not been observed. It has been suggested that Moraxella catarrhalis 
may provide indirect protection to S. pneumoniae via its β-lactamase production 
especially in a biofilm setting (9). So far, the most common method of S. pneumoniae 
resistance to β-lactam antibiotics is by altered penicillin-binding proteins. 
 
β-lactam Resistance Mechanisms Study 
Another aspect of my research included experiments that dealt with β-lactam 
resistance mechanisms. In an attempt to explain the mechanism of resistance to β-lactam 
antibiotics of the strains used in this study, BOCILLIN FL was used. BOCILLIN FL is a 
commercially available fluorescent penicillin (95). The concept of this study is based on 
the fact that most S. pneumoniae strains that are resistant to β-lactams have altered 
penicillin-binding proteins (PBPs) that would have less binding affinity to the antibiotics 
(27). Since BOCILLIN FL is a fluorescent penicillin, it would bind to the penicillin-
binding proteins which can be separated by SDS-PAGE and visualized under UV light. 
The altered PBPs would have a less affinity for BOCILLIN, hence less fluorescent 
intensity or none at all.  
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Preliminary results on the use of BOCILLIN FL to detect PBPs utilized two 
strains (Sp 95 and Sp G25053) based on their susceptibility results. These susceptible 
strains were chosen in order to use PBPs that do not have less binding affinity to 
BOCILLIN FL to optimize the system. There were two distinct bands visible in both 
strains. There were other bands scattered in the gel also. This shows that BOCILLIN FL 
was able to bind penicillin-binding proteins in the membrane fractions of Sp 95 and Sp 
G25053. These results however were not conclusive since there was no control present. 
In order for further studies to be conducted using BOCILLIN FL, a control would need to 
be obtained, such as purified PBPs. 
Another approach used in this study on S. pneumoniae β-lactam resistance was 
the generation of step mutants. The mutants were generated in an attempt to study the 
mechanisms of resistance that the mutants may have developed. S. pneumoniae strains 
were exposed to increased levels of ampicillin not unlike what may occur in a natural 
environment such as hospitals or livestock farms. Previous studies have used penicillin to 
generate step mutants in the same manner. Severin et al (73), generated mutants with 100 
fold increase to penicillin (from 0.02 to 2.0 µg/ml) and 20 fold increase (from 0.5 to 10 
µg/ml). The highest resistant S. pneumoniae strains isolated have generally had MICs to 
penicillin of 8 – 16 µg/ml (72). In this study, Sp G31159 was stepped up to 7 µg/ml from 
0.39 µg/ml and Sp Original was stepped to 5 µg/ml from 0.195 µg/ml ampicillin. The 





Natural Transformation of S. pneumoniae 
Another aspect of my research was to relate the antibiotic resistance of S. 
pneumoniae to horizontal gene transfer. One important process used by S. pneumoniae to 
acquire resistance genes is by natural transformation.  
Competence for transformation in Streptococci is not constitutive, as it is in Neiserria 
species, but is regulated by a quorum-sensing system encoded by two genetic loci, 
comCDE and comAB (45, 89). To date competence in S. pneumoniae has been 
demonstrated at densities ranging from (106 – 108) (23, 64). It has been suggested that in 
the natural environment (the nasopharynx) this could be important because if the cell 
density critical for competence is close to that which triggers host defenses, competence 
could then serve for adaptation of S. pneumoniae to host defense-generated stress (15). 
Other factors have been described that affect the expression of competence by S. 
pneumoniae. It has been shown that an increase of the pH of the medium continuously 
moved the competence peak to earlier exponential phase and thus to lower cell densities 
(48). A slightly basic pH seems to be optimal (7.4 to 8.0) and no competence has been 
detected at pH less than 7.0 (23, 48, 49, 81, 83). The reason being that the (Competence 
Stimulating Peptide) CSP is more active at alkaline than neutral pH (48). It has also been 
shown that in S. pneumoniae, Ca2+ is essential for growth, competence development, and 
autolysis (48, 49). Competence is induced optimally at 1 mM Ca2+. 
Another major factor affecting S. pneumoniae competence is serum. It was 
established by Hotchkiss and Tomasz in their pioneering work that serum albumin was 
required for S. pneumoniae natural transformation (34, 81). To date, the addition of 
serum has been maintained in transformation experiments (4, 29, 57-59). Finally, the 
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presence of capsule has been shown to abolish competence for natural genetic 
transformation in S. pneumoniae (8, 48, 66). 
 
Sp D2 Unknown Protein Analysis 
 Initial antibiotic susceptibility tests revealed that the clinical isolate Sp D2 from 
Duke University is resistant to all the β-lactam antibiotics that were tested namely; 
ampicillin, amoxicillin, ceftazidime, and penicillin G. The whole cell SDS-PAGE protein 
profiles also revealed a protein band approximately 50 kDa that was unique to Sp D2.
 A literature study was first conducted on PBPs in an attempt to determine if the 
unique protein of Sp D2 was in the size range of the known S. pneumoniae PBPs (Table 
1). All the S. pneumoniae PBPs that have been shown to contribute to β-lactam resistance 
have sizes between 70 kDa and 98 kDa. Only one, PBP3 is 43 kDa and has been shown 
not to participate in resistance development. The protein of interest being approximately 
50 kDa, did not fall within the resistance determining PBPs. A similar study was 
performed on the known virulence factors of S. pneumoniae and this protein still did not 
fall within any known virulence protein size ranges.  
 
SDS-PAGE of Cytoplasmic Membrane Fractions 
 Since PBPs are membrane bound enzymes, the membrane proteins of several of 
the strains were isolated including Sp D2 in attempt to determine if the unique protein is 
membrane bound. The membrane fractions were run on an SDS-PAGE gel (see Figure 
6). Initial studies (see Figure 3, Lane 3) revealed a highly concentrated band of 
approximately the same size as the protein of interest present in the Sp D2 lane but not in 
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any of the other strains tested. These preliminary studies indicated that the unique Sp D2 
protein was membrane bound even though it did not appear to be within the size range of 
the PBPs. The next steps were to further characterize the unique protein. 
 
MALDI-MS and MS/MS Peptide Analysis and Edman Degradation Sp D2 Protein  
 The protein of interest was excised from the membrane fraction SDS-PAGE gels 
and processed using an In-Gel trypsin digest kit. This kit allows the extraction of the 
protein band with subsequent trypsin digest. Trypsin cleaves after Lysine and Arginine 
residues (except if they are present before Proline) therefore producing specific 
fingerprints for specific proteins. The resulting peptides were then analyzed by MALDI-
MS (matrix-assisted laser desorption and ionization mass spectrometry). This is a mass 
spectrometry method that can, with great precision, determine the molecular weights of 
biological specimens. The peptide digests are mixed with the matrix material and then 
ionized with a laser. The longer it takes for the ionized material to travel to the detector, 
the larger its molecular weight. A spectra is thus produced (see Figures 9-14) reflecting 
the peptide masses and their relative abundance. The initial MS spectra is of the Sp D2 
intact peptides. From this spectra, the five most abundant peaks were selected (an 
automated procedure) and further fragmented by MS/MS (tandem ms). Both types of 
spectra display fingerprints unique to specific proteins and peptide sequences.  
 Three database were used to identify proteins by sequence similarity searches 
using the peptide sequences produced by the interpretation of the tandem mass spectra. 
The resulting protein hits are scored using a probability based Mowse score.  
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Mass spectrometry analysis indicated that only one protein CagA (from 
Helicobacter pylori) received a marginal significant score from the NCBInr and MSDB 
databases but not from the Swissprot database. As a result, this is not considered a true 
protein match. No protein was identified as having a significant score when searched 
against S. pneumoniae data available in all three databases. The proteins listed as the top 
scoring proteins from all databases do not share any apparent similarities. The MALDI-
MS and MS/MS results therefore did not provide a conclusive identification of the Sp D2 
unknown protein. Attempts to further analyze the MALDI-MS and MS/MS data and 
construct sequence tags by Dr Gorin and Dr, Day of Oakridge labs have been 
unsuccessful. 
 N- terminal and internal sequence data generated by Emory University 
microchemical facilities did not receive any significant hits with any database. We can 
therefore conclude that the Sp-D2 is a unique protein that has not been described before 
and is not present in the databases. 
 
Phase II of Research Studies 
Due to the inconclusive results obtained from the sequencing of the Sp D2 
protein, my research was refocused hence the second phase. It was determined that 
cloning and sequencing of the Sp D2 unknown gene was considered too time consuming 
and expensive.  
We therefore initiated a collaboration with Dr. Facklam and the Active Bacterial 
Core Surveillance/Emerging Infections Program Network at CDC to further study Sp D2 
and continued the studies to the other clinical strains presented in my thesis as well. We 
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further characterized Sp D2 to conclusively establish its taxonomic classification by, 
serotyping and analysis by PCR for the presence of pneumococcal surface protein (PsaA) 
gene, autolysin (lytA), and pneumolysin (ply) genes.   
S. pneumoniae is a member of the oral normal flora, among other Streptococcus 
species (S. oralis, S. mitis ) which exhibit alpha hemolysis (91).Three phenotypic tests 
(optochin susceptibility, bile solubility, and agglutination with the antipneumococcal 
polysaccharide capsule antibodies) were previously used to differentiate classical S. 
pneumoniae from those species.  Thus, atypical or variant S. pneumoniae strains  may be 
improperly classified on the basis of phenotypic characteristics.  
 
Additional Antibiotic Susceptibility Testing of Sp D2 
Additional antibiotic susceptibility tests were performed on Sp D2, using 
antibiotics not included in my initial thesis results. Sp D2 was found to be resistant to 
erythromycin, trimethoprim/sulfamethoxazole, and all β-lactams (see Table 6). Strains 
that are non-susceptible to three or more drug classes are considered to be multiply 
resistant (92). 
Sp D2 was found to be susceptible to four antibiotics, chloramphenical, 
tetracycline, clindamycin (a macrolide), levofloxacin and vancomycin. However, 
tetracycline, clindamycin and levofloxacin are not suitable for treatment of meningitis. 
This leaves only chloramphenical and vancomycin. Unfortunately, vancomycin must be 
administered intravenously to treat pneumococcal infections and its use tends to select for 
vancomycin-resistant Enterococci. The fluoroquinolones have drawbacks due to the ease 
of acquiring resistance by changing only one nucleotide in the DNA gyrase and relatively 
expensive (46). Thus an infection or outbreak caused by Sp D2 would present a serious 
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treatment problem. This being one of the reasons of interest by individuals of the 
Pneumococcal Molecular Epidemiology Network (PMEN).  
 
Serotype Studies and Additional Biochemical Characterization of S. pneumoniae Clinical 
Isolates 
 In order to further characterize Sp D2 and positively identify it as a S. 
pneumoniae, several characterization studies were undertaken. Additional biochemical 
tests used for the presumptive identification of S. pneumoniae were performed as well as 
serotyping studies on Sp D2 and all other clinical isolates in my research. 
Additional biochemical test results showed that was Sp D2 was positive by the 
optochin and bile solubility tests. These results are typical for S. pneumoniae strains. All 
the other strains except Sp G-5481 also tested positive by the bile solubility and optochin 
test. Sp Original showed variable results for the optochin test.  
Sp D2 was shown to be non-typeable. The most common serotype expressed by 
our clinical isolates was serotype 14 (six strains). The distribution of types isolated from 
adults differs substantially from that of types isolated from children. The most important 
pediatric serotypes (6A, 14, 19F and 23F) were responsible for almost 60% of all 
infections (2). In adults however, serotypes 3, 19F and 6A accounted for only 31% of the 
isolates (2). The serotypes 6B, 9V, 14, 19A, 19F, and 23F cause most drug-resistant 
infections in the United States (36).  
Two of our strains were serotype 19F; two were serotype 9V, and one was 
serotype 23F. It is significant to note that certain serotypes (6B, 9V, 14, 19A, 19F, and 
23F) have dominated the multidrug-resistant S. pneumoniae clones that have appeared 
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with different capsular serotypes. Such variants are thought to arise through natural 
transformation involving recombinational replacements with and around the capsular 
biosynthesis (cps) locus (17). Genes for the two PBPs are located on either side of the cps 
genes. Trzcinski et al., suggests that in natural habitats within the body, selection by host 
immunity and selection by antibiotics may be interrelated because of he effect of linkage 
of resistance determinants and capsule locus (85). However, it is significant to note that 
our strain (Sp D2) is nonencapsulated and multidrug resistant. 
Little information is available in the literature on the epidemiology of 
nonencapsulated S. pneumoniae populations. Whatmore et al., described a group of 
nonencapsulated strains that appeared genetically closely related to typical encapsulated 
strains (91). 
 
PCR Studies of Pneumococcal Surface Antigen, Autolysin and Pneumolysin Genes 
Although pneumococcus is the most common bacterial cause of pneumonia in 
children and adults worldwide, the diagnosis of pneumococcal pneumonia is difficult to 
establish. Blood cultures are positive in only 20%-30% of adults and less than 10% in 
children with pneumococcal pneumonia (10, 70). Sputum is also difficult to obtain and 
young children do not produce sputum. Further more, sampling via bronchioscope is 
laborious. As a result, rapid and reliable methods for diagnosis of pneumococcal 
pneumonia have been developed using PCR (polymerase chain reaction). The genes that 
have been targeted are the genes encoding pneumolysin, autolysin, and pneumococcal 
surface protein (69).  
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As a result of inconclusive identification of the unique Sp D2 protein by MALDI-
MS and Edman degradation studies, it was necessary to further characterize the strain and 
positively identify it as a S. pneumoniae. PCR studies were thus undertaken targeting 
common S. pneumoniae virulence encoding genes. The genes targeted were the 
pneumococcal surface protein (psaA) gene, autolysin (lytA), and pneumolysin (ply) 
genes.  
All strains were positive for the presence of pneumococcal surface antigen (psaA) 
gene. My psaA results correlate with the study of Morrison et al that demonstrated the 
presence of psaA in all 90 serotypes tested, and that there was lack of amplification of 
heterologous organisms. This suggested that PCR amplification of psaA could be a very 
useful tool for detection of pneumococci and diagnosis of disease. This also shows that a 
protein common to all serotypes with genetic and immunologic similarity has 
implications for both vaccine studies and diagnostics development. It means that the use 
of an immunogenic common protein as a vaccine could eliminate the need for multiple 
capsular types in a pneumococcal vaccine and additionally elicit a memory response, 
which occurs only with protein-based vaccines (61).  
All strains also showed the presence of autolysin (LytA) gene. Two strains, Sp-D6 
and Sp D-11 did not show an amplification of the pneumolysin (Ply) gene using outer 
primers but were positive with the inner primers. Two of the Grady strains Sp G-31159 
and G-5481 did not appear to have the pneumolysin gene based on the use of two sets of 
primers. There was no particular correlation between specific serotypes and gene 
amplified in this study. Although Sp G-5481 was non-typeable and did not appear to have 
the pneumolysin gene, it was determine to still fit the criteria of a S. pneumoniae 
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In clinical laboratories, identification of S. pneumoniae from other streptococci is 
important especially in cases where strains are not able to be serotyped. If a strain cannot 
be serotyped, an arbitrarily primed PCR with a single primer M13 universal is used as a 
method to distinguish S. pneumoniae from other upper respiratory tract streptococci (54). 
Sp D2 was positive by the arbitrarily primed PCR method. Although Sp D2 is non-
typeable, the additional biochemical tests as well as all the PCR studies positively 
identify Sp D2 as a S. pneumoniae.  
My thesis research has resulted in several significant findings: (i.) We have 
characterized Sp D2 as a nonencapsulated clinical isolate, that exhibits high level of 
resistance to erythromycin, trimethoprim/sulfamethoxazole, and several β-lactam 
antibiotics. These findings are sonsistent with the established criteria for a multidrug 
resistant strain. Strains that are non-susceptible to three or more drug classes are 
considered to be multiply resistant (92). (ii.) We have also partially characterized a 
membrane-bound protein in Sp D2 that is not associated with any PBPs., and (iii.) We 
have confirmed Sp D2 as expressing PsaA that encodes for the pneumococcal surface 
antigen A, the LytA that encodes autolysin, and the Ply that encodes pneumolysin; all of 
which establish criteria for classifying clinical isolates in the species of S. pneumoniae. 
Thus, these data suggest that Sp D2 may be an emerging clone that has acquired genes 






Sumary of Major Conclusions 
1. Sp D2 can be classified as a multi-drug resistant strain. 
2. Sp D2 is a non-typeable (does not react with any anticapsular antibody). Thus 
current polysaccharide vaccines would not be effective against Sp D2 
infections. 
3. Sp D2 showed the presence of pneumococcal surface antigen A, autolysin and 
pneumolysin encoding genes. 
4. Sp D2 was positive for bile solubility and optochin. 
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